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Interactions between RNA-binding proteins (RBPs) and RNAs are critical for 20 
cell biology. However, methods to comprehensively and quantitatively assess 21 
these interactions within cells were lacking. RNA interactome capture (RIC) 22 
employs in vivo UV-crosslinking, oligo(dT) capture and proteomics to identify 23 
RNA-binding proteomes. Recent advances have empowered RIC to quantify 24 





infection. Enhanced (e)RIC exploits the stronger binding of locked nucleic acid 1 
(LNA)-containing oligo(dT) probes to poly(A) tails to maximize RNA capture 2 
selectivity and efficiency, profoundly improving signal-to-noise ratios. The 3 
subsequent analytical use of SILAC and TMT proteomic approaches, together 4 
with high-sensitivity sample preparation and tailored statistical data analysis, 5 
significantly improves RIC’s quantitative accuracy and reproducibility. This 6 
optimized approach is an extension of the original RIC protocol. It takes three 7 
days plus two weeks for proteomics and data analysis, and will enable the study 8 
of RBP dynamics under different physiological and pathological conditions.  9 
 10 
INTRODUCTION 11 
Development of the protocol 12 
RIC employs irradiation of cultured cells with UV light to trigger crosslinks 13 
between protein and RNA interacting at ‘zero distance’. This is followed by cell 14 
lysis under denaturing conditions, specific isolation of polyadenylated (poly(A)) 15 
RNA and its covalently linked proteins using oligo(dT) magnetic beads and 16 
stringent washes and proteomic analysis1-3 (Fig.1). While effective to identify 17 
RBPs in multiple cell types1,2,4-7 and organisms8-13, RIC is not readily applicable 18 
to comparative analyses aiming to assess the responses of RBPs to 19 
physiological and pathological cues. In particular, the original protocol requires 20 
a substantial amount of starting material and lacks a specialized proteomics 21 
approach and tailored data analysis3. In the last years, several key 22 
improvements have empowered RIC to perform comparative analysis 23 
efficiently14,15. One of these key advances is the use of an oligo (dT) probe that 24 





bear a methylene bridge between the 2’-O and 4’-C atoms of the ribose ring. 1 
This modification “locks” oligonucleotides in the optimal conformation for base 2 
pairing with complementary strands, leading to a profound increase in the 3 
thermal stability of the nucleic acid duplex. By adding LNAs to the probe, it is 4 
possible to increase the stringency of the capture and washes, which 5 
profoundly depletes the sample of abundant non-poly(A) nucleic acids, such as 6 
rRNAs, as well as potential DNA contamination14,16. We describe here this 7 
improved variant of RIC that we refer to as enhanced RNA interactome capture 8 
(eRIC).  9 
To increase the quantitative power or RIC, we have successfully applied two 10 
different proteomic strategies that have already shown their efficacy in proof-11 
of-principle experiments14,15. The first approach exploits the capacity of stable 12 
isotope labelling with amino acids in cell culture (SILAC) to reduce technical 13 
noise by combining the samples after cell lysis (Fig.2). By mixing the lysates 14 
before the oligo(dT) capture, the isolation of poly(A) RNA and the downstream 15 
sample preparation for mass spectrometry becomes equally efficient for all the 16 
samples15. This, together with the high quantitative power of SILAC17, allows 17 
the discovery of even subtle changes in RBP activity15. SILAC allows to 18 
parallelize the analysis of up to three samples simultaneously, reducing mass 19 
spectrometry run time and improving cross-comparison accuracy when 20 
compared to label-free applications. While SILAC has been used in a broad 21 
range of cell lines and model systems, it cannot be easily applied to 22 
multicellular organisms or to cell types that do not tolerate SILAC reagents or 23 
that can only be cultured for a limited time. In such scenarios, it is 24 





isobaric labeling with tandem mass tag (TMT) (Fig.2). TMT labelling has been 1 
successfully used in RIC experiments applied to cultured cells and fruit fly 2 
embryos10,14, and can virtually be extended to any biological system. Isobaric 3 
labelling reagents allow higher level multiplexing with TMT enabling the 4 
analysis of up to sixteen samples in one mass spectrometry run. However, the 5 
RIC protocol is performed separately for each sample (Fig.2), potentially 6 
increasing technical noise. It is also recommended to perform sample 7 
fractionation and increase mass spectrometry analysis time to offset the 8 
reduction of protein identification rate and maximize proteome coverage.  9 
The original RIC protocol3 required a substantial amount of starting material, 10 
which is not feasible to obtain in many biological models. To reduce the amount 11 
of input material, we have combined eRIC with a recently-developed sample 12 
preparation approach, called ‘Single-pot solid-phase-enhanced sample 13 
preparation’ (SP3), that minimizes peptide loss18,19. As a reference, the eRIC 14 
workflow combined with SP3 reduces the amount of starting material by ~10 15 
fold, broadening its applicability.  16 
Moreover, the computational workflow used in the past was conceived to 17 
compare a UV-irradiated sample versus a non-irradiated control. This 18 
comparison yields relatively high fold changes, because the control is largely 19 
devoid of proteins. By contrast, the amplitude of the changes in comparisons 20 
of two UV-crosslinked samples that have been subjected to different treatments 21 
(e.g. uninfected versus infected cells) is expected to be lower, requiring high 22 
replicability to gain statistical power. We have implemented an analytical 23 
workflow that compiles the ratios between conditions, applies batch effect 24 





rate. In addition, our approach employs a complementary semiquantitative 1 
analysis to allow the study of proteins with ‘zero intensity’ values in one or more 2 
conditions. These results are problematic, as ‘zero’ values generate ‘zero’ or 3 
‘infinite’ ratios that cannot be, in principle, analyzed statistically10,14,15. This 4 
complementary semiquantitative analysis is important because it allows to 5 
study RBPs that switch from a dormant to an active RNA-binding state (off/on) 6 
and vice versa (on/off) . The importance of RBPs with these extreme behaviors 7 
is illustrated by IFI16 and IFIT5, whose RNA-binding activities are triggered 8 
upon Sindbis virus infection and are indeed critical antiviral host factors15.  9 
 10 
Applications and target audience 11 
Here, we describe a modified RIC protocol that is specifically designed to study 12 
RBP dynamics on a proteome-wide scale. Comparative RIC studies have 13 
recently been applied to profile RBP dynamics during embryo development10, 14 
virus infection15 and acute inhibition of alpha-ketoglutarate dependent 15 
dioxygenases14, revealing key regulators of these processes. Comparative RIC 16 
analyses have broad applications to understand how RBPs regulate RNA 17 
metabolism in response to developmental, physiological or environmental 18 
cues, including cell division, differentiation, reprogramming or stress. Given the 19 
importance of RBPs in disease20-23, this method can also be used to elucidate 20 
pathological mechanisms associated with e.g. infection, malignant 21 
transformation or metabolic disorders, as well as the modes of action of small 22 
molecules. Importantly, recent work has shown that RNA can regulate protein 23 
function in response to biological cues, a phenomenon that is referred to here 24 





identify examples of ‘riboregulation’26 in a proteome-wide manner. Given that 1 
the roles of cellular RNA and RBPs have been greatly expanded24-26,28-30, we 2 
foresee an extensive use of comparative RIC analysis not only by RNA 3 
biologists, but also by experts in other disciplines such as cell signaling, 4 
molecular medicine, development, immunology and virology.  5 
 6 
Advantages of (e)RIC and comparison to other methods 7 
eRIC approach described here shares the same advantages with its 8 
predecessor3, while adding specific features to efficiently study RBPome 9 
dynamics: (1) The improved workflow substantially reduces the required starting 10 
material, making it applicable to a broader range of biological systems; (2) UV 11 
light promotes RNA-to-protein crosslinks at ‘zero’ distances and does not induce 12 
detectable protein-protein crosslinks with the UV irradiation regime described 13 
here2,3,31,32; (3) UV irradiation is applied to living cells, thus providing information 14 
on native protein-RNA interactions and their dynamics; (4) The use of an 15 
oligo(dT) probe enriches for mRNAs and polyadenylated non-coding RNAs, 16 
reducing abundant non-polyadenylated RNAs, (e.g. rRNA and snRNA) and their 17 
associated proteins2,14. By depleting these dominant (e.g. ribosome-associated) 18 
proteins, RIC allows the detection of medium and low abundant RBPs bound to 19 
poly(A) RNA. The use of LNAs in the oligo(dT) probe strongly enhances 20 
selectivity14,16,33. (5) DNA is virtually undetectable in eluates of eRIC, even for cell 21 
types and experimental settings (e.g. nuclear fractionation) where DNA 22 
contamination was found to be problematic. (6) Incorporation of proteomic 23 
labelling strategies reduces the technical noise, improves quantification accuracy 24 





customized data analysis pipeline that allows the identification of subtle 1 
differences in RNA binding as well as a complementary  semiquantitative 2 
approach to deal with ‘zero’ values and investigate ‘on/off’ and ‘off/on’ RBP 3 
states14,15. (8) Importantly, RIC has successfully been applied to many organisms 4 
and cell lines1,2,4-13,25,34-36, thus offering solid foundations for adaptation to virtually 5 
every eukaryotic system. 6 
The original RIC protocol and its enhanced variant (i.e. eRIC) are based on the 7 
hybridization of an oligo(dT) probe with poly(A) tails and, thus, can only identify 8 
proteins interacting with poly(A) RNA. Recently, other RBP identification methods 9 
that also capture non-polyadenylated RNAs have been described37-43. Two 10 
approaches employed labelling of nascent RNA transcripts in cells with 5-11 
ethynyluridine (5-EU) and were referred to as RNA Interactome using Click 12 
Chemistry (RICK)37 and Click Chemistry-Assisted RNA Interactome Capture 13 
(CARIC)38. After UV-mediated crosslinking, cells are lysed, EU residues 14 
biotinylated via click chemistry and RNA-proteins conjugates purified with 15 
streptavidin-coated beads. While successful at identifying RBPs, these methods 16 
present some limitations such as the need of nucleotide incorporation, which is 17 
not readily applicable to all samples (e.g. organisms), can introduce biases 18 
towards highly transcribed genes and can be toxic44.  19 
2C39 and TRAPP40 build on the realization that silica-based matrixes do not only 20 
bind free RNA but also RNA with proteins covalently linked to it. After UV 21 
crosslinking, cells are lysed under strong denaturing conditions and RBPs 22 
purified using silica columns or beads. Although simple and potent, these 23 
approaches demand special considerations to avoid contamination with DNA-24 





eRIC was shown to almost completely prevent genomic (g)DNA contamination 1 
even in challenging systems exhibiting large gDNA/poly(A) RNA ratios, such as 2 
small cells (e.g. T lymphocytes)14 and isolated nuclei33.  3 
Global purification of RBPs was also achieved based on the physicochemical 4 
properties of covalent RNA-protein conjugates41-43. Acid guanidinium 5 
thiocyanate-phenol-chloroform extraction (“Trizol”) involves the generation of two 6 
phases, with RNA and proteins specifically locating to the aqueous and organic 7 
phase, respectively. XRNAX41 and OOPS42 purify RBPs with Trizol, exploiting the 8 
property of UV-crosslinked RNA-protein conjugates to migrate to the aqueous-9 
organic interphase. PTex43 is based on the same rationale, but in this case a 10 
neutral phenol-toluol extraction is used to remove DNA and membrane 11 
contaminants, followed by an acid-phenol extraction.  12 
The main advantage of all the methods based on total RNA purification is that 13 
they can be used to study RBPs that interact with non-poly(A) RNA (see below). 14 
However, as more than 90% of cellular RNA is composed of rRNA and tRNA, 15 
these methods are expected to be biased towards these highly abundant RNA 16 
biotypes. mRNA represents only a small fraction of total cellular RNA (~3%) and 17 
enrichment of poly(A) RNA with RIC/eRIC have been shown to be instrumental 18 
for a comprehensive characterization of poly(A) RNA-bound proteomes. Indeed, 19 
RBPomes generated with methods based on total RNA purification lack a 20 
significant fraction of RBPs identified by RIC/eRIC in identical systems37,38,40-43. 21 
These non-overlapping RBPs may interact exclusively or dominantly with poly(A) 22 
RNA.  23 
 24 





This protocol will not be suitable to study dynamics of RBPs that (i) shift in RNA 1 
preference but not in overall RNA binding; (ii) are not expressed or active in the 2 
experimental settings tested; (iii) bind exclusively non-polyadenylated RNA (e.g. 3 
prokaryotic RNA); (iv) exhibit a protein-RNA interface that is suboptimal for UV 4 
crosslinking (e.g. interaction only with the phosphate-ribose backbone); and (v) 5 
do not yield mass spectrometry compatible peptides. (vi) The efficacy of this 6 
protocol will also be compromised if the input material is extremely limited (we 7 
typically aim for 5-10 x107 cells) or if UV cannot penetrate the sample efficiently 8 
(e.g. thick tissue samples). 9 
As described above, RIC/eRIC are biased towards poly(A) RNA and cannot be 10 
used to study non-polyadenylated RNAs. Therefore, XRNAX41, OOPS42, PTex43, 11 
2C39 and TRAPP40 are especially useful when focusing on other (or all) classes 12 
of cellular RNAs including rRNA, snoRNA, snRNA and pre-mRNA. Indeed, these 13 
methods will be the best option to study bacterial systems where RNA (including 14 
mRNA) is not polyadenylated. In eukaryotic systems poly(A) RNA is a small 15 
fraction of the total RNA and, hence, the amount of starting material required to 16 
perform RIC/eRIC is substantially higher than that for total RNA purification 17 
approaches. Therefore, if the starting material is extremely limited, total RNA 18 
based methods will have higher chances to succeed at identifying RBPs. 19 
However, it is important to consider the substantial contribution of non-poly(A) 20 
RNA to the proteomic data. In summary, selection of the approach will depend 21 
on the specific aim of the project. RIC/eRIC will be the method of choice to study 22 
mRNA regulatory processes, while total RNA-based methods will be more 23 
appropriate when studying non-poly(A) RNA. Also, the availability of input 24 





based methods. In any case, we consider that both approaches are 1 
complementary and can be used in conjunction to generate a complete picture of 2 
the cellular RBPome.  3 
Experimental design 4 
Controls  5 
To identify contaminant proteins that may be present in the sample in a UV-6 
independent manner, we recommend including a control sample in which UV 7 
irradiation was omitted. If the availability of labels for the proteomic analysis is 8 
limited, a separate experiment including this control can be performed (as in 3) 9 
prior to the comparative analyses. If samples under study are very similar, a 10 
single non-irradiated control of a representative condition can be used. However, 11 
when comparing more profoundly different samples (e.g. different cell types, 12 
differentiation, long treatments, etc.), we strongly recommend parallelizing one 13 
non-irradiated control to each UV-irradiated sample/condition under study. To 14 
minimize the incidence of false positives, we typically classify as RBP any protein 15 
that is enriched in the UV irradiated over the non-irradiated control with 1% false 16 
discovery rate (FDR). For the comparative analysis, the ‘treated samples’ should 17 
be compared to a reference ‘untreated’ or ‘control’ condition. For example, cells 18 
infected with a virus would be compared to an uninfected control15. 19 
Total proteomic analysis of the cell lysates used as inputs for the eRIC 20 
experiment is a very informative addition. The protein intensity ratio between 21 
eluates and inputs represents the proportion of protein that crosslinks to RNA 22 
upon UV irradiation (crosslinked/total)15,36 (Fig. 3a-c). The eluate/input ratio will 23 
be influenced by the amino acid and nucleotide composition, geometry, avidity 24 





ability of a protein to crosslink to RNA25. For example, heterogenous 1 
ribonucleoproteins (hnRNPs) establish interactions with RNA that involve multiple 2 
high-affinity RNA-binding domains (RBDs). Such long-lived, optimal protein-RNA 3 
interactions will give rise to high eluate/input ratios15. Conversely, moderate to 4 
low eluate/input ratios are expected for RBPs establishing transitory interactions 5 
with RNA (e.g. endonucleases) or when only a subpopulation of the protein 6 
engages in RNA binding (e.g. moonlighting RBPs24,25,45). Moreover, we advise 7 
that proteins with low eluate/input ratios, which typically appear as outliers in the 8 
bottom-left corner of scatter plot (Fig. 3c), should be taken carefully as they may 9 
be contaminants or incidental RNA interactors. If interested in a protein falling 10 
into this category, we recommend validation with orthogonal methods. The 11 
eluate/input ratios have recently been used to model the RNA-binding activities 12 
present in large ribonucleoprotein complexes such as the exosome or the 13 
ribosome36. Other important applications of the eluate/input ratios are described 14 
in the anticipated results section. 15 
 16 
Selection of the proteomic approach  17 
We have successfully applied two quantitative proteomic approaches to perform 18 
comparative RIC analyses: SILAC and TMT.  Use of metabolic labeling (SILAC) 19 
aids precision and accuracy but possess limited multiplexing. Isobaric labeling 20 
such as TMT resolves the multiplexing issue but at the cost of accuracy. There 21 
are reviews describing the strength and weaknesses of these approaches46,47. 22 
SILAC involves the metabolic incorporation of heavy, medium or light isotopic 23 
amino acids into proteins in cultured cells (Fig. 2). For this, cells are grown in 24 





(typically) lysine and arginine. When using this approach, isotope incorporation 1 
rate must be measured in a pilot experiment. For efficient SILAC-based 2 
proteomics, near-complete incorporation rates are required, as lower 3 
incorporation rates will compromise the quantification accuracy. For example, 4 
if the isotope is incorporated only in 95% of the proteins it would cause on/off 5 
changes (i.e. present in condition A and absent in condition B) to be observed 6 
as a fold change of 19 (95 divided by 5). As proteins are labelled in cellulo, 7 
samples can be mixed immediately after UV crosslinking and cell lysis, and the 8 
RNA capture is performed with the combined samples. This reduces technical 9 
noise and enhances reliability and accuracy of the protein quantifications. 10 
However, the application of SILAC is mostly limited to cultured cells, and 11 
specifically to cell types that can be maintained in dialyzed serum. Cells are 12 
typically cultured for 5-6 population doublings in SILAC medium to reach high 13 
labelling efficiencies (>99%), and thus SILAC is not compatible, in principle, 14 
with cells that can only be cultured for a limited time (e.g. certain primary cells).   15 
Isobaric reagents such as TMT employ chemical labelling of peptides, and are 16 
thus applied after protein elution, concentration and digestion (Fig. 2). Post-17 
elution peptide labelling is compatible with virtually any biological system. The 18 
availability of numerous labels allows multiplexing of presently up to sixteen 19 
samples in a single run, in contrast to the three labels available for SILAC. The 20 
high multiplexing capability simplifies the execution of experiments with larger 21 
sample sets, such as those involving multiple treatment conditions or time 22 
points. Nevertheless, as peptide labeling is performed further downstream in 23 
the protocol, it does not benefit from the early pooling of samples to reduce 24 





Moreover, quantification is performed at the ms2 or ms3 level, and thus state-1 
of-the-art mass spectrometers are required for efficient and fast quantification. 2 
Quantification and identification with isobaric labelling are performed on the 3 
same peptide spectrum thus requiring the mass spectrometry method to strike 4 
a balance between identification efficiency and quantification quality. However, 5 
the higher ‘multiplexing’ of TMT reduces mass spectrometry time per sample, 6 
allowing the implementation of fractionation to address the identification and 7 
quantification loss. Separation of the sample into 3-5 fractions by, for example, 8 
high-pH reverse phase StageTip48 or other methods, is thus highly 9 
recommended. 10 
Both SILAC and TMT can, in principle, be extended to more conditions than 11 
labels available by running a complete experiment in multiple mass 12 
spectrometry runs and splitting the conditions between runs. In this case, it is 13 
a requisite to run a ‘reference’ sample (e.g. untreated cells) as a standard in 14 
each run, so that ratios between conditions can be robustly generated. 15 
In conclusion, we recommend using SILAC when possible, due to its higher 16 
robustness, especially when comparing up to three conditions. TMT or similar 17 
isobaric tagging strategies will be the approach of choice when using SILAC-18 
incompatible cells, tissues or organisms. It will also be the optimal choice when 19 
assessing a large set of conditions. Fractionation is highly recommended when 20 
performing TMT experiments.  21 
Although SILAC and TMT provide the highest quantification accuracy and 22 
multiplexing capacity, RIC/eRIC can be combined with virtually any quantitative 23 
proteomic approach. For example, a recent study has applied label-free 24 






DNA vs LNA probes  2 
We and others have shown that the use of conventional oligo (dT) DNA capture 3 
probes in RIC experiments can lead to contamination with non-poly(A) RNAs 4 
such as rRNA. Indeed, depending on the cell type employed and the 5 
experimental settings, rRNA can represent from 10% to 30% of the eluted RNA 6 
1,2,14. Proteins that copurify with these abundant non-polyadenylated RNAs 7 
(e.g. ribosomal proteins) generate dominant tryptic peptides that mask those 8 
from less abundant RBPs. Co-purification of gDNA can also be problematic as 9 
it could lead to contamination with DNA-binding proteins or proteins 10 
nonspecifically tangled on the chromatin fibers. This can critically impact the 11 
quality of RIC experiments when working with nuclear fractions or cells with a 12 
low cytoplasm/nucleoplasm ratio such as T lymphocytes. Both contamination 13 
with non-polyadenylated RNAs and gDNA can be strongly reduced when using 14 
a 20-mer oligo(dT) probe containing locked nucleic acids (LNAs) at every other 15 
position (LNA2.T)14. LNAs increase the rigidity of the probe promoting an 16 
optimal conformation for hybridization with complementary RNA. The original 17 
RIC protocol employs very stringent purification conditions, focused on 18 
removing non-covalently linked proteins from the RNA. The increased 19 
hybridization strength that the inclusion of LNAs in the oligo(dT) probe 20 
provides, allows to additionally maximize the selectivity of the protocol towards 21 
poly(A) RNAs. For example, in eRIC the capture of poly(A) RNA and 22 
subsequent washes are performed at 37 °C instead of 4 °C. Moreover, it 23 
includes a ‘pre-elution’ (final wash) step in water to remove partial hybrids and 24 





pre-elution step destabilizes nucleic acid duplexes, particularly partial hybrids, 1 
resulting in efficient removal of rRNA and gDNA (Fig. 4).  2 
Here, we describe how to perform comparative RIC studies with the LNA2.T 3 
beads (i.e. eRIC), due to the remarkable advantages that this probe adds to 4 
the protocol. However, the original DNA oligo(dT) beads have also been 5 
successfully used in comparative RIC experiments10,15,36. If using the original 6 
DNA probe, apply the experimental design and protocol described here but 7 
employ 4 °C during the hybridization step and washes and omit the pre-elution 8 
step. Elution can be performed by heating (at 55°C for 3 min) or RNase release 9 
as indicated below.  10 
 11 
Starting material 12 
Incorporation of SP3 together with modifications in the protocol and 13 
improvements on mass spectrometry instrumentation have allowed to 14 
considerably reduce the starting material required to generate a deep RBPome. 15 
For example, we have achieved deep RBPomes from ~50-90 million HeLa and 16 
HEK293 cells or ~100-150 million Jurkat cells. For orientation, an optimal eRIC 17 
experiment should lead to ~15-30 g of eluted poly(A) RNA per sample to ensure 18 
successful downstream proteomic applications. We have noticed that in some 19 
cell lines, such as T lymphocytic cells, nuclear RBPs are substantially more 20 
abundant than their cytoplasmic counterparts. In such cases, peptide 21 
fractionation prior to mass spectrometry greatly improves the identification and 22 






RIC and case-specific variations of it have successfully been applied to several 1 
unicellular5,8,9,12,34,36 and multicellular organisms8,10,11,35 and it is applicable to 2 
tissues13. Starting material and other parameters such as UV light dose must be 3 
adapted to the system under study. An excellent starting point is to use the 4 
conditions described in the original publications5,8-13,34-36, and to further optimize 5 
the protocol with small-scale pilot experiments, if required. 6 
  7 
Successive rounds of capture 8 
To maximize poly(A) RNA capture, we perform two sequential rounds of oligo(dT) 9 
capture of the same lysate, using 300 L of oligo(dT) magnetic beads per round. 10 
While two rounds of oligo(dT) capture suffice, in most cases, to capture most 11 
poly(A) RNAs from cell extracts, a third round could be required in some 12 
instances. To evaluate if the poly(A) RNA depletion has been sufficient, RNA 13 
present in each elution round should be measured with e.g. a NanoDrop, 14 
separately. Near complete depletion of poly(A) RNA in the lysate leads to a strong 15 
reduction in the RNA isolated in the following round of oligo(dT) capture due to 16 
the lack of suitable substrate to hybridize with the probe. For example, a third 17 
round of oligo(dT) capture typically leads to only 15-10% of the RNA isolated in 18 
the first round. In such case, we only recommend performing 2 rounds of capture 19 
as the contribution of a third to the proteomic results will be residual. 20 
The efficiency of the oligo(dT) capture can be estimated more accurately using 21 
RT-qPCR analysis using primers against selected poly(A) RNAs (e.g. ACTB or 22 
GAPDH) in cell lysates before and after the oligo(dT) capture. An efficient eRIC 23 
experiment will reduce the levels of a given poly(A) RNA by at least 80%. 24 






eRIC optimization 2 
When applying eRIC for the first time to a given cell line, tissue or organism, we 3 
recommend performing small-scale experiments (Fig. 1 and Fig. 4). RNA in 4 
inputs and eluates can be quality controlled using bioanalyzer and RT-qPCR to 5 
assess the proportion of poly(A) RNA versus rRNA. A strong enrichment of 6 
poly(A) RNA (e.g. ACTB mRNA) over rRNA (e.g. 18S rRNA) is expected in 7 
eluates when compared to inputs (Fig. 4a; see ‘anticipated results’). In parallel, 8 
RBP isolation can be tested by silver staining (Fig. 4b) or western blotting using 9 
antibodies against well-established RBPs and negative controls (e.g. PTBP1 and 10 
ACTB, respectively)3. RIC’s ability to efficiently isolate RBPs and poly(A) RNA is 11 
typically dictated by few key steps that benefit from optimization. These include 12 
the i) amount of starting material, ii) the UV crosslinking approach, iii) the cell lysis 13 
procedure, and the iv) homogenization of the cell lysate. Optimal starting material 14 
is thus fundamental to achieve efficient eRIC experiments. Lack of proteins in 15 
eluates despite good quality RNA can often be solved by increasing the number 16 
of cells. Still, some cell types (e.g. primary T cells, primary macrophages), give 17 
inherently low number of proteins even from large amounts of captured RNA. 18 
Conversely, high incidence of contaminant proteins can be caused by excessive 19 
protein, RNA and DNA concentration in lysates. We have already estimated the 20 
optimal number of cells for HeLa, HEK293 and Jurkat (as indicated in ‘Starting 21 
material’ above). However, cell numbers may need adjustment when working 22 
with other cell types. Correct estimation of the starting material becomes more 23 
challenging when dealing with multicellular organisms and tissues. In those 24 





RNA interactions with UV light (see below). Improving UV crosslinking efficiency 1 
will effectively reduce the input material required; however, excessive UV 2 
irradiation can lead to protein and RNA damage. 3 
UV crosslinking can be achieved either exploiting the natural excitability of 4 
nucleotide bases at 254 nm (conventional crosslinking; CL)49 or employing 5 
nucleotide analogues such as 4-thiouridine (4SU) or 4-thiouracil (4TU) that 6 
promote efficient crosslinking between 312 and 365 nm UV light 7 
(photoactivatable ribonucleoside-enhanced crosslinking; PAR-CL)50. While CL 8 
suffices for most cell lines and is readily applicable to tissues and multicellular 9 
organisms, PAR-CL has shown higher performance in budding and fission 10 
yeast5,36. Hence, the choice of the crosslinking approach will depend on the 11 
model system.  12 
Moreover, UV crosslinking efficiency may differ depending on the properties of 13 
the sample. When using cell monolayers, 150 mJ/cm2 of 254 nm UV is a good 14 
balance between crosslinking efficiency and lack of RNA damage. However, the 15 
optimal dose might vary slightly from cell line to cell line. Conversely, tissues and 16 
multicellular organisms may require substantially higher UV irradiation regimens. 17 
For example, the optimal UV dose for Drosophila embryos is 4 J/cm2 10.  18 
Cell lysates are viscous and one of the key optimization steps is to find the optimal 19 
proportion between lysis buffer, biological material and beads. For example, we 20 
found that 10 mL of lysis buffer and 300 µL of beads are optimal for selective 21 
RBP capture for ~50-90 million HeLa cells or 100-150 million Jurkat cells. Cell 22 
lysates are homogenized using a 5 mL syringe and a narrow needle until a water-23 
like solution is achieved. This step is critical as it promotes the disruption of 24 





and avoiding the generation of precipitates. If despite of an efficient 1 
homogenization, precipitates are observed, increase the lysis buffer volume, 2 
homogenize as indicate above and pre-clear the lysate by centrifugation prior to 3 
the oligo(dT) capture.  See TROUBLESHOOTING.  4 
 5 
HPLC and mass spectrometry parameters  6 
For a successful comparative eRIC experiment it is critical to have a suitable 7 
proteomic workflow in place. Sample preparation can be performed with any 8 
classical technique, including filter-aided sample preparation (FASP)51 or TCA 9 
precipitation52. However, to increase sensitivity while reducing the starting 10 
material, we employ SP318,19,53. This approach allows efficient removal of 11 
detergents and other mass spec-incompatible chemicals, while ensuring efficient 12 
protein trypsinization and peptide recovery.  13 
In some experimental settings (see ‘selection of the proteomic approach’), 14 
peptide fractionation is required to improve protein coverage. In those cases, we 15 
apply high pH reversed-phase peptide fractionation54 or similar approaches55,56 16 
prior to LC/MS analysis. The number of fractions can vary in a case-specific 17 
manner, but five fractions normally suffice to provide an excellent depth. Peptides 18 
are analyzed on a liquid chromatography–tandem mass spectrometry (LC-19 
MS/MS) platform. We used an Ultimate 3000 ultra-HPLC system (ThermoFisher 20 
Scientific) coupled to an Orbitrap Elite, QExactive or QExactive plus mass 21 
spectrometer (Thermo Fisher Scientific)14,15. However, it is possible to use other 22 
equipment with similar characteristics and performance. During LC/MS analysis, 23 
each fraction is further separated on low pH gradient of solvent B, the composition 24 





and it should be adjusted for maximum protein identification. Specific mass-1 
spectrometric parameters (such as dynamic exclusion, collision energy, etc) are 2 
dependent on the instrument. The current protocol does not require any specific 3 
adjustments and can be adapted to virtually any platform optimized for routine 4 
protein identification. We recommend monitoring the LC-MS performance 5 
between samples and/or fractions by running a blank sample spiked with 20 fmol 6 
digested BSA on a 15 min gradient after each sample and/or fraction. BSA 7 
digests have characteristic standard chromatographic peaks, which can be used 8 
as a proxy to assess the performance of the nanoflow HPLC. Moreover, it will 9 
help to clean carryover contaminants between samples. 10 
 11 
Statistical data analysis 12 
For robust statistical analysis, it is recommended to generate at least three 13 
biologically independent replicates of the complete experimental set, which will 14 
include the reference condition (e.g. uninfected cells), treatments (e.g. virus 15 
infected cells) and, depending on the experimental design, a negative control 16 
(e.g. non-irradiated cells). For more details see ‘controls’. Experimental 17 
conditions causing subtle variations in the RBPome or with high intrinsic inter-18 
sample variability (e.g. clinical samples), may require higher number of replicates. 19 
Peptides are identified and clustered into protein groups and quantified using 20 
standard software such as MaxQuant57. Ion counts across samples are 21 
summarized and protein intensity ratios between conditions are generated. 22 
Significance of the changes is tested using moderated t-test corrected for multiple 23 
testing with a Benjamini-Hochberg correction. Software implementation (e.g. 24 





instances, data normalization and/or batch corrections are required. Analysis of 1 
comparative RIC/eRIC experiments are done in two sequential steps. We first 2 
compare protein intensities in UV-irradiated and non-irradiated controls and 3 
define as RBPs those proteins that are enriched in irradiated over non-irradiated 4 
samples with 1% FDR. Secondly, responsive RBPs are identified by comparing 5 
the protein intensities of each RBP in crosslinked samples subjected to the 6 
different experimental conditions. To define the RBP responses it is critical to 7 
avoid normalization against non-irradiated samples, as signal in these controls is 8 
low and noisy and provokes artificial distortions of the data when used as 9 
normalizer. We typically classify as ‘high-confidence’ or ‘candidate’ dynamic RBP 10 
any protein that passes the 1% and 10% FDR cut-offs, respectively.  11 
Unfortunately, it is not trivial to analyze RBPs with missing ion counts in one 12 
experimental condition due to the impossibility to generate a ratio. There are two 13 
alternatives to deal which such cases and ‘rescue’ genuine RBPs (if comparing 14 
irradiated vs non-irradiated samples) or responsive RBPs (if comparing two 15 
experimental conditions). The first employs a semi-quantitative analysis that 16 
takes into consideration the incidence of signal in one condition and lack of signal 17 
in the other10,15. Alternatively, it is possible to impute missing values using 18 
different computational approaches59. The minimum determination method 19 
(Mindet)59 is one of the most commonly used strategies, in which the missing 20 
values are replaced by the lowest value detected either globally in the entire 21 
dataset or within each sample. Either option has strengths and weaknesses: 22 
while the semi-quantitative method does not require the imputation of artificial 23 
values, it does not provide ratios to estimate the amplitude of the effect, which 24 





ratios and thus these RBPs can be included in the statistical analysis. However, 1 
imputation methods can introduce artefacts that may affect the statistical 2 
analysis. In any case, we recommend applying either strategy.   3 
 4 
Complementary analyses  5 
Cellular stimuli often trigger changes at multiple levels, including transcriptomic 6 
and proteomic changes. In order to identify the driving factors of the RBP 7 
responses we recommend combining comparative RIC analyses with both total 8 
proteome and transcriptome analyses. These analyses will provide a snapshot of 9 
the protein and RNA landscapes in the experimental conditions, which can be 10 
used to interpret the RIC/eRIC results. In other words, the parallel analysis of 11 
both protein and RNA abundance is instrumental to determine if any (or both) of 12 
these factors contribute to the comparative RIC results10,15. These 13 




Reagents  18 
Biological materials 19 
 20 
 HeLa cells (ATCC, cat. no. CCL-2; 21 
https://scicrunch.org/resolver/CVCL_0030)  22 
 Jurkat cells (DSMZ, cat. no. ACC-282, 23 





CAUTION: The cell lines used should be regularly checked to ensure they 1 
are authentic and are not infected with mycoplasma.  2 
Cell culture reagents 3 
 DMEM (Thermo Fisher Scientific, cat. no. 11995065)  4 
 DMEM for SILAC (Thermo Scientific, cat. no. 88364) 5 
 RPMI 1640 (Thermo Fisher Scientific, cat. no. 21875034)  6 
 RPMI-1640 for SILAC (SILANTES, cat. no. 283001300) 7 
 Fetal bovine serum (FBS; Thermo Fisher Scientific, cat. no. 10500064)  8 
 Glutamine (Gibco, cat. no. G7513)  9 
 Penicillin/streptomycin (Sigma-Aldrich, cat. no. P4333) 10 
 Dialysed fetal bovine serum (SILANTES, cat. no. 281000900) 11 
 Unlabeled L-Arginine HCl (SILANTES, 201004102). C6H14N4O2 •HCl  12 
 13C-, 15N-labelled L-Arginine HCl (SILANTES, cat. no. 201604102). 13 
13C6H1415N4O2 •HCl  14 
 13C-labelled L-Arginine HCl (SILANTES, cat. no. 201204102). 15 
13C6H14N4O2 •HCl 16 
 Unlabeled L-Lysine HCl (SILANTES, cat. no. 211004102). 17 
C6H14N2O2 •HCl  18 
 13C-, 15N-labelled L-Lysine HCl (SILANTES, cat. no. 211604102): 19 
13C6H1415N2O2 •HCl 20 
 2H-labelled D4 L-Lysine 2HCl (SILANTES, cat. no. 211104113). 21 
C6D4H10N2O2 •2HCl. D, deuterium  22 
 Sterile filter 0.22 µm pore size (Millipore cat no: SCGVU05RE) 23 






eRIC reagents 2 
 Potassium chloride (KCl) (Merck, cat. no. 1.04936.1000) 3 
 Potassium dihydrogen phosphate (KH2PO4) (Merck, cat. no. 4 
1.04873.1000) 5 
 di-Sodium hydrogen phosphate (Na2HPO4) (Merck, cat. no. 6 
1.06586.0500) 7 
 Sodium chloride (NaCl) (Merck, cat. no. 1.06404.1000) 8 
 Calcium chloride (CaCl2) (Merck, cat. no. 1.02382.1000) 9 
 RNase T1 (Sigma-Aldrich, cat. no. R1003) 10 
 RNase A (Sigma-Aldrich, cat. no. R5503) 11 
 Complete Protease Inhibitor Cocktail (Roche, cat. no. 11873580001)  12 
 Trizma base (Sigma-Aldrich, cat. no. T1503)  13 
 Lithium dodecyl sulfate (LiDS) (Carl Roth, cat. no. CN25.3)  14 
CAUTION: Harmful if swallowed or inhaled. Can cause serious eye 15 
damage. Wear suitable protective equipment, especially when handling as 16 
powder. 17 
 Lithium chloride (LiCl) (Sigma-Aldrich, cat. no. 62476) 18 
 Ethylenediaminetetraacetic acid (EDTA) Disodium Salt, Dihydrate (Merck, 19 
cat. no. 324503) 20 
 Dithiothreitol (DTT) (Biomol, cat. no. 04020.100) 21 
 IGEPAL® CA-630 (Nonidet P-40 (NP-40) replacement) (Sigma-Aldrich, 22 
cat. no. I3021) 23 





CAUTION: Harmful if swallowed or inhaled. Can cause serious eye 1 
damage. Wear suitable protective equipment, especially when handling as 2 
powder. 3 
 Triton X-100 (Sigma-Aldrich, cat. no. T8787) 4 
 Sodium deoxycholate (Sigma-Aldrich, cat. no. D6750) 5 
CAUTION: Harmful if swallowed. Causes skin irritation and serious eye 6 
irritation. May cause respiratory irritation. Wear dust mask type N95 (US), 7 
protective goggles and gloves. 8 
 Pierce™ 660nm Protein assay kit (Thermo Scientific, cat. no. 22662) 9 
 Ionic Detergent Compatibility Reagent (Thermo Scientific, cat. no. 22663) 10 
 11 
Reagents for generation of LNA probes  12 
 LNA2.T capture probe: 13 
/5AmMC6/+TT+TT+TT+TT+TT+TT+TT+TT+TT+TT (+T: LNA thymidine, 14 
T: DNA thymidine) (HPLC purified; Exiqon-Qiagen). The probe bears a 15 
primary amine at the 5’ end followed by a flexible C6 linker and 20 16 
thymidine nucleotides in which every other nucleotide is an LNA. The 17 
required scale of synthesis will depend on the number of samples and 18 
capture rounds. A detailed description on this subject is provided in section 19 
´Coupling of the LNA2.T probe to beads´. 20 
 Carboxylated magnetic beads M-PVA C11, 50 mg/mL (Perkin Elmer, cat. 21 
no. CMG-203) 22 





 N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC-HCl) 1 
(Sigma-Aldrich, cat. no. E7750). CRITICAL Store EDC powder at -20 °C, 2 
when required handle it on ice. It is highly hygroscopic, so check that 3 
powder is dry before using it.  4 
CAUTION: Toxic on contact with skin. Causes serious eye irritation. Wear 5 
protective gloves and eye protection. Very toxic for aquatic environments. 6 
Follow suitable disposure procedures  7 
 ≥98% (wt/vol) ethanolamine (Sigma-Aldrich, cat. no. E9508) 8 
CAUTION: Harmful if swallowed, in contact with skin or if inhaled. Causes 9 
severe skin burns and eye damage. Wear protective gloves and eye 10 
protection. Very toxic for aquatic environments. Follow suitable disposure 11 
procedures 12 
 Nuclease-free water (Ambion, cat. no. AM9937) 13 
 Tween® 20 (Carl Roth, cat. no. 9127.2) 14 
CRITICAL Alternatively, oligo(dT) (DNA) probes [Oligo(dT25) magnetic beads 15 
(New England Biolabs, cat. no. S1419S)] can be used instead of the LNA2.T 16 
probes. If so, use 4 °C instead 37 °C during the capture and washes and omit 17 
pre-elution. 18 
 19 
Mass spectrometry and SP3 reagents 20 
 1M Tetraethylammonium tetrahydroborate (TEAB) (Thermo Fisher 21 
Scientific, cat. no. 90114) 22 
 SP3 purification beads: Speed Bead Magnetic Carboxylate Modified 23 





CRITICAL Note that these beads are for sample preparation for 1 
proteomics and not for poly(A) RNA capture. 2 
CAUTION: Azide is highly toxic, wear gloves and avoid contact with skin. 3 
 Reduction buffer: Bond-Breaker™ TCEP Solution (Thermo Fisher 4 
Scientific, cat. no. 77720) 5 
CAUTION: Causes severe skin burns and eye damage. Wear gloves, 6 
clothing and face/eye protection. 7 
 Chloroacetamide (CAA) (Sigma-Aldrich, cat. no. C0267) 8 
CAUTION: Toxic if swallowed. May cause allergic skin reaction. Wear 9 
protective gloves and clothing. 10 
 Absolute Ethanol (Sigma-Aldrich, cat. no. 34852) 11 
 Acetonitrile (ACN) (Sigma-Aldrich, cat. no. 271004) 12 
 Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, cat. no. 34869)  13 
 Water LC-MS Grade (Pierce, cat. no. 51140) 14 
 Trypsin Gold, MS grade (Promega, cat. no. V5280) 15 
 16 
TMT reagents:  17 
 TMT Isobaric Label Reagent TMT10plex (Thermo Fisher Scientific, cat. 18 
no. 90111) Alternatively, duplex TMT, Sixplex TMTTMT11plex, or TMTpro 19 
16plex can be used according to the number of samples.  20 
 OASIS HLB µElution Plate (Waters, cat. no. 186001828BA) 21 
 22 
Reagents for eRIC quality assessment 23 





 TURBO DNA-free Kit (Life Technologies, cat. no. 1907) 1 
 SuperScript II reverse transcriptase (Invitrogen, cat. no. 18064-014) 2 
 SYBR Green PCR Master Mix (Life Technologies, cat. no. 4309155) 3 
 Random hexamers (Life Technologies) 4 
 Antibodies (Table 1) 5 
 qPCR primers for human samples (Table 2) 6 
 qPCR primers for mouse samples (Table 3)  7 
 8 
Antigen Company, catalogue RRID Dilution 
β-Actin  Sigma-Aldrich, A1978 AB_476692 1:5000 
Histone H4  Abcam, ab10158 AB_296888 1:4000 
Polypyrimidine tract 































Table 2. qPCR primers for quality assessments of eRIC eluates of human 5 
origin. All sequences from 5′ to 3′, forward: Fw, reverse: Rv. Note that GAPDH 6 
and ACTB forward and reverse primers are designed to target a unique exon of 7 
the respective gene and are suitable to quantify both gDNA and cDNA levels.    8 
 9 
Name Sequence  
Hm ACTB Fw  GTCATTCCAAATATGAGATGCGT 
Hm ACTB Rv  GCTATCACCTCCCCTGTGTG 
Hm GAPDH Fw  CCCCACCACACTGAATCTCC 
Hm GAPDH Rv  GTACATGACAAGGTGCGGCT 
Hm 18S rRNA Fw  GAAACTGCGAATGGCTCATTAAA 
Hm 18S rRNA Fw  CACAGTTATCCAAGTGGGAGAGG 
Hm 28S rRNA Fw  TTACCCTACTGATGATGTGTTGTTG  
Hm 28S rRNA Rv  CCTGCGGTTCCTCTCGTA 
Name Sequence 
Ms Bact Fw  AGAGGGAAATCGTGCGTGAC 
Ms Bact Rv  CAATAGTGATGACCTGGCCGT 
Ms Gapdh Fw  AACGACCCCTTCATTGACCT 
Ms Gapdh Rv  ATGTTAGTGGGGTCTCGCTC 






Table 3. qPCR primers for quality assessments of eRIC eluates of mouse 2 
origin. All sequences from 5′ to 3′, forward: Fw, reverse: Rv. Note that GAPDH 3 
and ACTB forward and reverse primers are designed to target a unique exon of 4 
the respective gene and are suitable to quantify both gDNA and cDNA levels.    5 
 6 
Equipment  7 
 Class II biosafety cabinet (generic)  8 
 Humidified 37 °C, 5% CO2 incubator (generic) 9 
 Spectrolinker XL-1500 UV cross-linkers (Spectroline) (254 nm bulbs, BLE-10 
1T155) 11 
 Rotator (e.g. Grant-bio, PTR-35) 12 
 Conventional incubator without humidification or CO2 control at 37 °C used 13 
for the oligo(dT) capture (Aqualytic, Thermostat Cabinet or similar)  14 
 SpeedVac concentrator (Thermo Fisher Scientific)  15 
 Refrigerated benchtop centrifuge (e.g. Eppendorf, 5415R) 16 
 Thermal block (e.g. Eppendorf, cat. no. 5382000015)  17 
 500 cm2 dishes (Greiner-BioOne, cat. no. 639160) – for adherent cells  18 
 175 cm2 flasks (Falcon, cat. no. 353028) – for suspension cells  19 
 150 mm uncoated petri dishes (Greiner Bio-One, 639102) – for 20 
suspension cells  21 
Ms 18S rRNA Rv  GGGACTTAATCAACGCAAGC 
Ms 28S rRNA Fw  AAGCGTTGGATTGTTCACCC 





 Generic metal plate to accommodate 2 x 150 mm petri dishes into the UV 1 
crosslinker - for suspension cells 2 
 500 mL Steritop Quick Release-GP funnel (Millipore, cat. no. 3 
S2GPT05RE) 4 
 Needle 22G × 1 1/4-inch; Nr. 12, 0.7 mm × 30 mm (BD Microlance, cat. 5 
no.  300900) or alternatively Sterican blunt Needle 21G, 0.8 x 22 mm 6 
(VWR, cat. no. 720-2562).  7 
CAUTION: handle needles with precaution to avoid harm. We recommend 8 
using blunt variants. Dispose the needles in the appropriate sharp bin. 9 
 Sterican blunt Needle 27G, 0.4 x 25mm (VWR, cat. no. 720-2563) 10 
CAUTION: handle needles with precaution to avoid harm. We recommend 11 
using blunt variants. Dispose the needles in the appropriate sharp bin. 12 
 Syringes (5 mL; Luer-lock; Medicina, cat. no. IVL05)  13 
 DNA LoBind tubes (Eppendorf, 1.5 mL: cat. no. 022431021; 5.0 mL: cat. 14 
no. 0030108310; 15 mL: cat. no. 0030122208; 50 mL: cat. no. 15 
0030122232) 16 
 Magnetic separation rack, 50 mL (NEB, cat. no. S1507S). For analytical 17 
experiments, 12-tube (2 mL) Magnetic separation rack (NEB, cat. no. 18 
S1509S) or DynaMag-2 (Invitrogen, cat. no. 123.21D) 19 
 NanoDrop spectrophotometer (Thermo Fischer Scientific) 20 
 Bioanalyzer with RNA 6000 Pico Kit (Agilent Technologies, cat. no. 5067-21 
1513 and G2939BA)  22 






 Tandem mass spectrometer (e.g. Thermo Scientific Orbitrap Fusion, Q-1 
Exactive, Bruker Impact II or similar) 2 
 3 
Software for proteomic data analysis 4 
 Protein identification by database searching: Mascot (MatrixScience, 5 
http://www.matrixscience.com/distiller_download.html), Sequest (Thermo 6 
Fisher Scientific, http://www.selectscience.net/products/sequest-7 
cluster/?prodID=10319#tab-2) or Andromeda60 (via MaxQuant 57). 8 
 Protein quantification: MaxQuant (https://maxquant.org/)57. 9 
 R software (http://www.r-project.org/) 10 
 Bioconductor software (http://www.bioconductor.org/), in particular, limma 11 
(https://bioconductor.org/packages/release/bioc/html/limma.html)61. 12 
 13 
Reagent setup  14 
Cell culture and SILAC reagents 15 
 Cell culture media: HeLa cells and Jurkat cells are maintained in DMEM 16 
or RPMI-1640, respectively. These media are supplemented with 10% 17 
(vol/vol) fetal bovine serum (FBS), glutamine, penicillin/streptomycin, and 18 
cells are maintained in a humidified incubator at 37 °C and 5% CO2. 19 
 Cell culture media for SILAC: For SILAC, combine medium without 20 
arginine and lysine (DMEM for HeLa or RPMI-1640 for Jurkat), with 10% 21 
(vol/vol) dialyzed FBS. Prepare one bottle for each SILAC labelling 22 
condition by adding either unlabeled arginine and lysine (light medium), 23 
13C L-Arginine HCl and 2HD4 L-Lysine 2HCl (medium labeled medium) or 24 





Use 84 mg/L arginine and 146 mg/L lysine for DMEM and 200 mg/L 1 
arginine and 40 mg/L lysine for RMPI-1640. Filter the media with a 0.2 µm 2 
Sterilefilter and store at 4 °C for up to 3 months. 3 
eRIC reagents  4 
 Phosphate-buffered saline (PBS): combine 0.2 g/L KCl, 0.2 g/L KH2PO4, 5 
1.15 g/L Na2HPO4 and 8 g/L NaCl. Prepare, autoclave and store at room 6 
temperature for up to 1 year.  7 
 1 M DTT stock:  prepare 5 mL aliquots in distilled (d)H2O and store at −20 8 
°C for up to 1 year. 9 
 1 M Tris-HCl (pH 7.5): dissolve 121 g Trizma base in 800 mL dH2O. Adjust 10 
pH to 7.5 with concentrated HCl. Bring volume to 1 L, autoclave and store 11 
at room temperature for up to 1 year. 12 
 0.5 M EDTA (pH 8.0): dissolve 186.1 g of EDTA disodium salt dihydrate in 13 
700 mL dH2O. Adjust pH to 8.0 with 10 N NaOH. Bring volume to 1 L, 14 
autoclave and store at room temperature for up to 1 year. 15 
 10% wt/vol LiDS: dissolve 30 g of LiDS in dH2O to a final volume of 300 16 
mL, sterilize by filtration and store at room temperature for up to 1 year. 17 
 Lysis buffer: 20 mM Tris-HCl (pH 7.5), 500 mM LiCl, 1 mM EDTA, 5 mM 18 
DTT and 0.5% (wt/vol) LiDS. Prepare 1 L without DTT, sterilize by filtration 19 
and store at room temperature for up to 1 year. Add DTT and Complete 20 
protease inhibitor cocktail immediately before usage.  21 
 Buffer 1: 20 mM Tris-HCl (pH 7.5), 500 mM LiCl, 1 mM EDTA, 5 mM DTT 22 
and 0.1% (wt/vol) LiDS. Prepare 1 L without DTT, sterilize by filtration and 23 
store at room temperature for up to 1 year. Add DTT and Complete 24 





 Buffer 2: 20 mM Tris-HCl (pH 7.5), 500 mM LiCl, 1 mM EDTA, 5 mM DTT 1 
and 0.02% (vol/vol) NP40. Prepare 1 L without DTT, sterilize by filtration 2 
and store at room temperature for up to 1 year. Add DTT and Complete 3 
protease inhibitor cocktail immediately before usage. 4 
 Buffer 3: 20 mM Tris-HCl (pH 7.5), 200 mM LiCl, 1 mM EDTA, 5 mM DTT 5 
and 0.02% (vol/vol) NP40. Prepare 1 L without DTT, sterilize by filtration 6 
and store at room temperature for up to 1 year. Add DTT and Complete 7 
protease inhibitor cocktail immediately before usage. 8 
 10x RNase buffer: 100 mM Tris-HCl (pH 7.5), 1.5 mM NaCl and 0.5% 9 
(vol/vol) NP-40. Store up to 1 year at 4 °C. 10 
 RNase A solution. Prepare 10 mg/mL stock in Tris-HCl (pH 8.0) and 50% 11 
(vol/vol) glycerol, aliquot and store at -20 °C. 12 
 Heat elution buffer: 20 mM Tris-HCl (pH 7.5) and 1 mM EDTA. Autoclave 13 
and store at room temperature for up to 1 year. 14 
 RIPA buffer: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% (wt/vol) SDS, 15 
0.5% (wt/vol) sodium deoxycholate, 1% (vol/vol) Triton X-100. 16 
 17 
Coupling reagents 18 
 50 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer pH 6. Prepare, 19 
filter and store at room temperature for several months protected from light 20 
by covering the bottle with aluminum foil.   21 
 20 mg/mL N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 22 





 200 mM ethanolamine pH 8.5. Add 2.493 mL of 98% (wt/vol) ethanolamine 1 
to ~150 mL of dH2O. Adjust pH with 10 N NaOH and bring to 200 mL with 2 
H2O. Store at room temperature for several months. 3 
 1 M NaCl. Store at room temperature indefinitely. 4 
 0.1% (vol/vol) PBS-Tween. Store at room temperature for several months. 5 
 6 
Coupling of the LNA2.T probe to beads, Timing 8 h 7 
Commercial DNA oligo(dT) probes used in the original protocol are already 8 
coupled to magnetic beads (New England Biolabs, S1419S). Conversely, the 9 
LNA-containing probe, LNA2.T, must be coupled to magnetic beads with free 10 
carboxylic groups on their surface. Below, we describe the process for coupling 11 
the probe to the beads.   12 
1. Calculate the required amounts of LNA2.T probe and of carboxylated 13 
beads. We employ 30 nmol of probe (300 µL of a 100 µM solution) coupled 14 
to 15 mg of beads (300 μL of the original 50 mg/mL bead suspension) for 15 
one round of capture per sample. Note that LNA2.T coupled beads can be 16 
reused, at least, up to five times without noticeable loss in performance. 17 
We recommend producing enough LNA2.T coupled beads to perform all 18 
the biological replicates with the same batch. The following steps show the 19 
volumes required to produce LNA2.T-coupled beads for one round of 20 
capture in one sample. To obtain final volumes, multiply the indicated 21 
volumes of LNA2.T probe and beads by the number of samples and 22 
rounds of capture (typically two rounds). The size and number of tubes will 23 
depend on the amount of LNA2.T-coupled beads and derived final buffer 24 





2. Spin down tube with lyophilized LNA2.T probe. Add 1 mL nuclease free 1 
water per 100 nmol of probe to obtain 100 μM concentration. Vortex for 30 2 
seconds and spin down briefly.  3 
PAUSE POINT. Probe solution can be stored at −20 °C at least for several 4 
months.  5 
3. Wash 15 mg of beads (300 μL of 50 mg/mL suspension) three times with 6 
5 volumes of MES buffer pH 6.  7 
4. Freshly prepare 1.5 mL of a 20 mg/mL solution of the coupling activator 8 
EDC-HCl in MES buffer. Transfer a small aliquot (~25 μL) of the EDC 9 
solution to a new 1.5 mL tube. This will be used as blank to estimate the 10 
coupling efficiency (see below). 11 
5. Collect the beads from step 3 on a magnet and discard the supernatant. 12 
Remove from magnet and reserve. 13 
6. Combine 1.5 mL of EDC solution with 30 nmol of probe (300 μL of 100 µM 14 
probe solution). Transfer a small aliquot (~25 μL) of this probe-EDC 15 
solution to a fresh 1.5 mL tube to estimate coupling efficiency (see below).  16 
7. Add 1.8 mL of probe-EDC solution (step 6) to 15 mg of beads (step 5) and 17 
resuspend.  18 
8. Incubate for 5 h at 50 °C and 800 rpm in a thermal block, occasionally 19 
spinning down the liquid that condenses on the lid. Incubate likewise the 20 
small aliquots collected for quality control analysis i.e. EDC solution (step 21 
4) and probe-EDC solution (step 6).   22 
9. Collect the beads with a magnet. Take a small aliquot (~25 μL) of 23 





three ~25 μL test samples collected in steps 4, 6 and 9 and keep them at 1 
room temperature (15-25 ºC). 2 
10. Wash beads with 1.75 mL of PBS. Repeat wash once. 3 
11. Incubate with 1.5 mL 200 mM ethanolamine pH 8.5 for 1 h at 37 °C and 4 
800 rpm to inactivate any residual carboxyl residue. Meanwhile estimate 5 
coupling efficiency as explained in the next section. 6 
12. Using a magnet, wash the LNA2.T-coupled beads three times with 1.75 7 
mL of 1 M NaCl. 8 
13. Collect the beads with a magnet and resuspend in 300 μL of PBS 9 
supplemented with 0.1% (vol/vol) Tween-20. If performing the coupling 10 
reaction in multiple tubes in parallel, combine them into a single tube of 11 
appropriate size to correct for potential coupling differences and 12 
subsequent batch effects. PAUSE POINT Coupled beads can be stored 13 
at 4 °C for at least three months. Supplement with 0.02 % sodium azide 14 
as preservative for longer storage.  15 
14. Estimate the probe concentration in the probe-EDC solution collected 16 
before (step 4) and after (step 9) coupling in a NanoDrop device at 260 17 
nm wavelength, using the EDC solution (i.e. without probe) taken in step 18 
4 as a blank. A robust drop on the absorbance after coupling should be 19 
observed.  20 
 21 
Recycling of probe-coated beads 22 
CRITICAL LNA2.T-coupled magnetic beads can be reused several times (at least 23 
five times). Before reusing the beads, the RNase A/T1-resistant poly(A) stretches 24 





should also be washed several times for removal of any trace of poly(A) tails and 1 
RNases. 2 
CRITICAL Steps 1-4 should be performed immediately after eRIC.  3 
1. Resuspend 300 μL of the used beads in 400 μL of nuclease-free water 4 
and transfer them into a 1.5 mL low binding tube. 5 
2. Incubate at 95 °C in a thermal block at 800 rpm for 5 min. Proceed and 6 
collect the beads immediately after, using a magnet, to prevent the sample 7 
from cooling down. Discard supernatant.  8 
3. Resuspend beads in 5 volumes of water. We recommend pooling the 9 
beads used for the different conditions to ensure a homogeneous bead 10 
batch for subsequent captures. Wash three times with 5 volumes of water, 11 
using the magnet to collect the beads.   12 
4. Wash the beads three times with 5 volumes of lysis buffer, if the LNA2.T-13 
beads will be used immediately after, or with 5 volumes of PBS 14 
supplemented with 0.1% (vol/vol) Tween-20 for longer term storage at 15 
4 °C. PAUSE POINT Recycled beads can be stored for at least three 16 
months. If required, supplement with 0.02 % sodium azide as preservative 17 
for longer storage. Beads can be successfully re-used for at least five 18 
times.  19 
5. Before re-using the beads stored in PBS-Tween-20, wash three times with 20 
five volumes of lysis buffer.  21 
 22 
Commercial DNA oligo(dT) magnetic beads used in the original RIC protocol can 23 






SP3 reagents 1 
 100 mM TEAB. Prepare it from a 1M TEAB stock solution in LC/MS-grade 2 
H2O immediately before use. 3 
 Alkylation buffer. Prepare 500 mM Chloroacetamide (C-IAA) stock solution 4 
by dissolving 0.0467 g of CAA in 1 mL of 100 mM TEAB.  This must be 5 
prepared immediately before use. 6 
 Wash buffer 1: 70% (vol/vol) Ethanol (EtOH) (vol/vol) in LC/MS-grade 7 
H2O. Prepared fresh and keep at RT for up to 1 week. 8 
 Wash buffer 2: 100% Acetonitrile (ACN). 9 
 Trypsin digestion buffer: Use freshly prepared 50 mM TEAB in LC/MS-10 
grade H2O for SILAC or 50 mM HEPES pH 8.5 in LC/MS-grade H2O for 11 
TMT.  12 
 SP3 elution buffer: 2% (vol/vol) DMSO in LC/MS-grade H2O for SILAC or 13 
50 mM HEPES pH 8.5 in LC/MS-grade H2O for TMT. Prepare immediately 14 
before use. 15 
 Mass spectrometry loading buffer: Prepare 5% (vol/vol) DMSO and 5% 16 
(vol/vol) formic acid in LC/MS-grade H2O. Keep at 4 °C for one week.  17 
 18 
SP3 purification bead stock preparation: 19 
1. Remove bottle of SP3 purification beads from fridge and keep it at room 20 
temperature for 10 minutes.  21 
2. Mix 40 µL of bead slurry with 160 µL of water (LC/MS grade). 22 
3. Place tube on a magnetic rack and let the beads settle for 2 minutes. 23 





4. Resuspend the beads in 200 µL of water (LC/MS grade), collect the 1 
beads with a magnet and discard the supernatant. Repeat this step 2 
twice. 3 
5. Store SP3 purification beads (10 µg/µL) in 200 µL of water at 4 °C. This 4 
stock suffices for up to twenty samples and can be stored for up to one 5 
month.  6 
 7 
PROCEDURE 8 
CRITICAL If you are using SILAC-based proteomics start at step 1, otherwise 9 
go to step 4. 10 
Incorporation of labelled amino acids in adherent or suspension cells 11 
Timing: 14 days.   12 
1. Grow three separate populations of cells for 5-6 passages in SILAC 13 
media. Each of the three cell populations should be maintained in media 14 
lacking arginine and lysine, supplemented with 10% (vol/vol) dialyzed FBS 15 
and one set of isotopic labelled arginine and lysine (i.e. light, medium or 16 
heavy amino acids, as described in ‘Cell culture and SILAC reagent setup’). 17 
CRITICAL STEP: Make sure you do not switch cells from a given isotopic 18 
amino acid combination to another e.g. cells growing with heavy arginine and 19 
lysine must always be maintained with these heavy amino acids.  20 
2. Seed one 6 cm dish with each cell population (i.e. incubated with light, 21 
medium or heavy amino acids) and keep them in their respective media 22 
overnight at 37 °C and 5% CO2. Lyse the cells with 500 µL of RIPA buffer 23 
supplemented with protease inhibitors and confirm isotope incorporation by 24 






CRITICAL STEP: It is required a high incorporation rate (optimally >98%) to 2 
continue with the experiment. 3 
3. Freeze aliquots of each SILAC-labeled cell population with their 4 
respective SILAC medium supplemented with 20% (vol/vol) dialyzed FBS 5 
and 10% (vol/vol) DMSO. It is possible to initiate any comparative RIC/eRIC 6 
experiment from these frozen cell stocks starting from step 4. 7 
PAUSE POINT. Cells can be stored indefinitely in liquid nitrogen. 8 
 9 
Cell preparation for eRIC. Timing 1-2 days. 10 
For adherent cells follow option A and for suspension cells follow option B. 11 
Seeding densities for HeLa and Jurkat cells are provided as a reference. 12 
CRITICAL STEP: If using SILAC, labels should be permutated between 13 
conditions in different biological replicates to correct for incidental unlabeled 14 
contaminants (e.g. keratins from skin) and potential isotope-driven effects. 15 
4.  16 
A. Adherent cells 17 
i. Seed 1 x 500 cm2 dish per condition with ~1.1 x 107 HeLa 18 
cells (or 3 x 150 mm dishes per condition with 3 x 106 cells 19 
per dish). If using SILAC you must assign one label to each 20 
condition at this stage (e.g. condition A> light; condition B> 21 
medium; condition C> heavy). Incubate the cells at 37 °C and 22 
5% CO2 until 80% confluent (usually 1-2 days) and apply the 23 
desired physiological, pathological or pharmacological 24 





B. Suspension cells 1 
i. Seed 3 x 175 cm2 flasks per condition with Jurkat cells at a 2 
density of ~0.5 x 106 cells/mL. If using SILAC you must 3 
assign one label to each condition. Incubate cells in a 4 
humidified incubator at 37 °C and 5% CO2 until reaching a 5 
density of 1-1.5 x 106 cells/mL (typically 1-2 days, with 30-45 6 
x 106 cells/175 cm2 flask) and apply the desired 7 
physiological, pathological or pharmacological treatment.  8 
TROUBLESHOOTING 9 
 10 
UV irradiation and cell lysis. Timing: 1-2 h  11 
5. See Option A if working with adherent cells and Option B if working with 12 
suspension cells. 13 
A Adherent cells 14 
i. Aspirate carefully the culture media of one dish and wash 15 
twice with 15 mL of ice-cold PBS. After the second wash tilt 16 
the plate on ice for a few seconds to collect remaining PBS 17 
and remove it by aspiration. Proceed quickly to the next step. 18 
ii. Remove the lid of the dish and place the dish inside the 19 
crosslinker in an appropriate ice chamber at 15-30 cm from 20 
the UV source. Irradiate with the dish on ice with 150 mJ/cm2 21 
of 254 nm UV light. Proceed quickly to the next step.  22 
iii. Add 10 mL of ice-cold lysis buffer supplemented with protease 23 





scraper. Transfer the lysate to a 50 mL conic tube and place 1 
it on ice.  2 
 3 
B Suspension cells 4 
i. Ensure that cells are monodispersed by pipetting multiple times 5 
using a 25 mL pipette. Take an aliquot and test viability (e.g. with 6 
trypan blue). 7 
CRITICAL STEP: only proceed if cells show high viability (optimally 8 
>90%). 9 
ii. Collect 100-130 x 106 living cells by centrifugation at 400 × g for 10 
5 min at 4 °C. Resuspend in 30 mL of ice-cold PBS and split into 11 
two 150 mm uncoated petri dishes with no lids. Proceed quickly to 12 
the next step. 13 
CRITICAL STEP: Use uncoated petri dishes to avoid cells attaching 14 
to the surface. If cells attach to the uncoated surface, use dishes 15 
with low cell binding surfaces instead (e.g. HydroCell, Nunc). 16 
iii. Deposit the petri dishes containing the cells on an ice-cooled metal 17 
block and place inside the crosslinker at 15-30 cm from the UV 18 
source. Irradiate with 150 mJ/cm2 of 254 nm UV light. Proceed 19 
quickly to the next step. 20 
iv. Transfer the cell suspension from the petri dishes to a pre-cooled 21 
50 mL conical centrifuge tube and keep on ice. Tilt the dishes on 22 
ice for 30 seconds and collect the remaining cell suspension 23 
accumulated on the bottom. Combine with the rest in the 50 mL 24 





CRITICAL STEP. Check the dishes with a brightfield microscope. If 1 
a large number of cells remains on the dish surface, add 10 mL ice-2 
cold PBS and pipet up and down to recover them. Combine with 3 
the rest of the suspension. Repeat if necessary.  4 
v. Pellet the cells at 400 × g for 5 min at 4 °C. Working on ice, discard 5 
the supernatant and lyse immediately after with 10 mL of ice-cold 6 
lysis buffer supplemented with protease inhibitors. Keep on ice. 7 
 8 
CRITICAL STEP: We recommend applying a 300 mJ/cm2 program to the 9 
crosslinker immediately before irradiating the cells. This will warm up the bulbs 10 
and make UV irradiation cycles more homogeneous. UV crosslinkers typically 11 
have a sensor in the bottom-deep part of the chamber. Make sure the ice 12 
chamber or metal block does not occlude the sensor. 150 mJ/cm2 UV irradiation 13 
typically takes from 30 to 60s. If the irradiation takes longer, make sure the UV 14 
sensor is not occluded and all the bulbs are in working order. 15 
6. Repeat step 5 with the rest of the dishes/conditions until all samples 16 
are processed. 17 
 18 
Lysate homogenization. Timing: 60 min  19 
7. Working on ice, homogenize the lysate to shear genomic DNA and 20 
any remaining cellular structures. Do so by passing each sample 3 21 
times through a 5 mL syringe with a 22-Gauge (0.7 mm diameter) 22 
needle. As the volume of the lysate is larger than 5 mL, transfer the 23 





CAUTION: During the homogenization steps, extra care needs to be taken 1 
while working with syringes and needles in order to avoid injuries. We 2 
recommend the use of blunt needles and syringes with Luer-Lock. Additionally, 3 
extra care is recommended to avoid spillage, particularly, when removing the 4 
plunger from a syringe. 5 
CRITICAL STEP: Efficient homogenization is critical for successful RIC 6 
experiments. As the strength required to pass the lysate through the needle relies 7 
on the plunger area, syringes bigger than 5 mL are not recommended. To obtain 8 
optimal homogenization, apply as much pressure as possible on the syringe’s 9 
plunger, releasing the lysate against the wall of the 50 mL tube to avoid the 10 
generation of foam. When almost all the lysate has passed through the needle, 11 
reduce pressure as this also prevents the generation of foam. Apply all these 12 
considerations to the next step. 13 
   14 
8. Repeat step 7 with a 27-Gauge needle (0.4 mm diameter) until the 15 
lysate has lost its viscosity, which typically takes three or more 16 
homogenization cycles with the 27-Gauge needle. 17 
 TROUBLESHOOTING    18 
9. Either snap freeze the samples in liquid nitrogen and store at −80 °C 19 
or proceed directly to step 11.  20 
PAUSE POINT: Samples can be stored at −80 °C for up to one month. We 21 
recommend avoiding repeated freeze thaw cycles. 22 
CRITICAL STEP: If using SILAC, you can stop at this stage until all the 23 
biological replicates are collected. As the different conditions from each 24 





50 mL tube per replicate). Hence, it is feasible to proceed with all 3 replicates 1 
in parallel. This parallel processing of replicates will notably reduce technical 2 
variation and subsequent batch effects. 3 
  4 
RNP capture. Timing: 2-4 hs.  5 
10. Thaw samples in a 37 °C water bath and continue to the next step 6 
immediately after defrosting. 7 
11. (optional) Incubate samples at 60 °C for 15 min, quickly cool down on 8 
ice and centrifuge at 16000 × g for 5 min and 4 °C to remove any 9 
insoluble material. Transfer supernatant to a fresh 50 mL low-binding 10 
conical centrifuge tube. NOTE: This step is particularly recommended 11 
when lysates look turbid and/or gDNA/protein contaminants had been 12 
detected in the eluates of a previous eRIC experiment. If none of 13 
these apply to your samples, you can omit this step. 14 
TROUBLESHOOTING 15 
CRITICAL STEP: Incubate simultaneously 1 mL of lysis buffer at 60 °C for 15 min 16 
for use in protein quantification in step 13.     17 
12. Take 2% of the volume of each sample as ‘input’ control and store at 18 
-80 °C.  19 
13. Estimate protein concentration of each sample using an ionic 20 
detergent compatible commercial kit and following manufacturer’s 21 
recommendations.  22 
CRITICAL STEP: Not all protein assays are compatible with the ionic detergent 23 
and DTT concentration contained in the lysis buffer. We recommend Pierce 24 





(IDCR) (Thermo Fisher Scientific). Importantly, prepare the protein standard in 1 
the same lysis buffer to correctly calibrate the assay. If step 11 was performed, 2 
use an aliquot of lysis buffer incubated at 60 °C for 15 min as blank and to dilute 3 
the protein standard, as DTT influences protein quantification and is unstable at 4 
high temperatures.  5 
14. If optional step 11 was applied, supplement the lysate with 5 mM DTT 6 
from 1 M stock to compensate for DTT loss.  7 
15.  If using SILAC see A, if using other proteomic approach (e.g. TMT) 8 
go to B. 9 
A. SILAC 10 
i. Transfer the volume corresponding to an equal amount of protein 11 
from each sample into a single 50 mL tube to combine samples. 12 
Adjust the combined volume with lysis buffer to 10 mL per sample.  13 
CRITICAL STEP: Volumes indicated ‘per sample’ across the 14 
protocol will be multiplied by the number of SILAC samples 15 
combined in this step. 16 
B. TMT (or other proteomic approaches) 17 
i. Transfer the volume corresponding to an equal amount of protein 18 
of each sample into separate 15 mL tubes. Adjust the volume of 19 
each tube to 10 mL with lysis buffer.  20 
CRITICAL STEP: The amount of protein used is determined by the sample with 21 
the lowest protein mass. For example, if sample A=10 mL at 1 mg/mL and 22 
sample B=10 mL at 2 mg/mL, 10 mg of protein will be used (corresponding to 10 23 





16. Add 300 L/sample of LNA2.T beads to the tube and mix by 1 
pipetting up and down (e.g. use 900 µL for SILAC if 3 samples were 2 
combined). 3 
17. Incubate for 30 min at 37 °C with gentle rotation. 4 
18. Collect beads with a magnet in a thermostat cabinet at 37 °C. Wait 5 
until the lysate is fully clarified. This should not take more than a few 6 
min. 7 
19. Transfer supernatant to a new tube (50 mL tube for SILAC and 15 mL 8 
tube for TMT) and use it for the second round of capture (step 21).  9 
20. Add 5 mL of ice-cold lysis buffer to the LNA2.T beads from step 18. 10 
Keep them at 4 °C.  11 
21. Repeat steps 16 to 18 for the second round of LNA2.T capture. 12 
Proceed with the next steps simultaneously with the beads from the 13 
first and second round of capture.  14 
CRITICAL STEP: Once the protocol is successfully implemented for a given 15 
cell type and thus the quality of the outcome of each round of capture is 16 
known, the beads from the first and second capture can be combined here. 17 
Bead combination reduces the number of tubes, which is especially 18 
recommended if the experimental design includes numerous conditions. If the 19 
beads are combined, double the volumes throughout the protocol from step 20 
22. 21 
22. After the second round of capture (step 21), collect the beads and 22 
transfer supernatant to a new tube and store at -80 ºC for quality 23 
control purpose or proceed to a third capture cycle if required (see 24 





Resuspend the bead pellet from the first and second capture in 10 1 
mL/sample of lysis buffer at room temperature. Incubate for 5 min at 2 
37 °C with gentle rotation in a thermostat cabinet. Collect the beads 3 
using a magnet and discard the supernatant.  4 
CRITICAL STEP. For this and the consecutive washes steps, it is essential 5 
that the beads are monodispersed and do not clump as this can promote the 6 
purification of contaminants. Resuspend the beads by pipetting up and down 7 
with a 5 mL pipette. If clumps are observed, resuspend in the following 8 
washes gently in 1 mL of the corresponding buffer using a p1000 micropipette 9 
with a low binding tip and then add the remaining volume of buffer. The 10 
narrower exit of the p1000 tip facilitates clump disruption. 11 
23. Resuspend the beads with 10 mL/sample of buffer 1 (kept at room 12 
temperature) and incubate for 5 min at 37 °C with gentle rotation. 13 
Collect the beads on the magnet and discard the supernatant. Repeat 14 
this step once.  15 
24. Resuspend the beads with 10 mL/sample of buffer 2 (kept at room 16 
temperature) and incubate for 5 min at 37 °C with gentle rotation. 17 
Collect the beads on the magnet and discard the supernatant. Repeat 18 
this step once.  19 
25. Resuspend the beads with 10 mL/sample of buffer 3 (kept at room 20 
temperature) and incubate for 5 min at 37 °C with gentle rotation. 21 
Collect the beads on the magnet and discard the supernatant. Repeat 22 
this step once.  23 
CRITICAL STEP. In the final wash, make sure that the supernatant has been 24 





26. For the pre-elution step, resuspend the beads in 220 µL/sample of 1 
nuclease-free water and transfer to 1.5 mL low-binding tubes. 2 
Incubate in a thermal block at 40 °C and 800 rpm for 5 min. 3 
CRITICAL STEP: The pre-elution step should reduce potential contamination 4 
with rRNA and gDNA without compromising poly(A) RNA capture when using 5 
LNA2.T probe. However, this step is not compatible with the commercial DNA 6 
oligo(dT) probe used in the original protocol3. Hence, if using commercial DNA 7 
oligo(dT) beads, skip this step. 8 
TROUBLESHOOTING. 9 
27. Transfer 20 µL/sample of the bead suspension to a fresh 1.5 mL low-10 
binding tube for RNA and DNA quality control analyses. Capture 11 
beads with a magnet and discard the supernatant (which contains 12 
eluted contaminants). Add 15 L of heat elution buffer and store on 13 
ice until step 33.   14 
 15 
RNase-based elution for protein analysis. Timing: 60-90 min 16 
28. Place the remaining sample from step 26 (200 μL/sample upon 17 
removal of 20 µl in step 27) on a magnet rack. Transfer supernatant 18 
(which contains eluted contaminants) to a new tube and keep it on 19 
ice.  20 
CRITICAL STEP: We recommend keeping this supernatant when adapting the 21 
protocol to a new cell type or organism, especially if the yield of captured RNA 22 
is low, as it can be used for quality control purposes (see RNA and DNA 23 





29. For RBP elution, resuspend beads in 150 μL/sample of freshly 1 
prepared RNase solution (prepare according to the table below) and 2 
incubate for 30 min at 37 °C and 800 rpm.  3 
Component   For 150 μL    For 450 μL* 4 
Water    133.65 μL    401 μL 5 
10x RNase buffer  15 μL (final: 1x)   45 μL 6 
1M DTT   0.75 μL (final: 5 mM)  2.25 μL 7 
10 mg/mL RNase A 0.2 μL (final: ~100 U)  0.6 μL 8 
RNase T1   0.5 μL (final: ~100 U)  0.5 μL 9 
*use if 3 SILAC samples were combined 10 
CRITICAL STEP: During this incubation perform steps 33 and 34. 11 
30. Collect the beads on a magnetic rack and transfer supernatant to a 12 
fresh 1.5 mL low-binding tube.  13 
CRITICAL STEP: captured proteins are now in the supernatant. 14 
31. Combine the supernatants of the first and second round of LNA2.T 15 
capture (see steps 22-25) if performing a proteomic experiment. Keep 16 
them separate if performing a pilot experiment.  17 
32. Place samples from step 31 on a magnet to eliminate any remaining 18 
traces of beads. Transfer supernatant to a new 1.5 mL low-binding 19 
tube. 20 
PAUSE STEP: Eluted proteins can be snap frozen in liquid nitrogen and stored 21 
at -80 °C indefinitely or be processed immediately (step 44). 22 
Heat elution for RNA/DNA analysis. Timing: 15 min 23 
33. Elute captured RNA from the aliquots taken in step 27 by incubating 24 
for 5 min at 95 °C and 800 rpm. Proceed immediately to next step, 25 





34. Collect the beads with a magnet and quickly transfer supernatant to 1 
a new 1.5 mL low-binding tube. Place the sample again on a magnet 2 
to eliminate any remaining traces of beads and transfer the 3 
supernatant to a new low-binding 1.5 mL tube.    4 
PAUSE STEP: Samples can be snap frozen in liquid nitrogen and stored at -80 °C 5 
for at least one month. 6 
Quality control analyses  7 
RNA and DNA analyses. Timing: 2d 8 
CRITICAL When adapting eRIC to a new biological model, we recommend to 9 
analyse RNA and DNA levels on eluates of each round of capture separately.  10 
35. Isolate the total RNA from 50 µL of input (step 12) using TRIzol (follow 11 
the manufacturer’s protocol).  12 
36. Determine RNA concentration in samples from step 34 (eRIC heat 13 
eluates) and step 35 (purified input RNA) in a NanoDrop device.   14 
Assessment of quality and purity of captured RNA by capillary 15 
electrophoresis (bioanalyzer) 16 
37. Take 1 μL aliquots of heat eluates (Step 34) and of the purified RNA 17 
from inputs (Step 35) and adjust RNA concentration to 5 ng/μL with 18 
nuclease free water.  19 
38. Run 5 ng (i.e. 1 μL) of each sample in a Bioanalyzer using the Agilent 20 
RNA 6000 Pico Kit following manufacturer´s indications. See Fig. 4a 21 
for an example of the expected outcome.  22 
TROUBLESHOOTING.  23 





39. Mix 0.2-1 μg of RNA from eRIC heat eluates (Step 34) and inputs 1 
(Step 35) with TURBO DNase mixture (see below), and incubate for 2 
30 min at 37 °C in a thermal block. eRIC eluates treated with TURBO 3 
DNase will be used to measure RNA and will be then referred to as 4 
eRIC-RNA. Treat identically and simultaneously an equal amount of 5 
eRIC eluates but replacing the DNase by water. These samples will 6 
be employed to estimate gDNA contamination and are thus referred 7 
to as eRIC-gDNA. It is not required to perform this mock treatment 8 
with input samples. 9 
Component    Reaction  Mock reaction 10 
RNA     0.2-1 μg  0.2-1 μg 11 
10x TURBO DNase buffer  1 μL   1 μL 12 
TURBO DNase   1 μL   - 13 
Nuclease free water   up to 10 μL  up to 10 μL 14 
 15 
40. Add 2 μL of TURBO DNase Inactivation Reagent to eRIC-RNA, 16 
eRIC-gDNA and input samples and proceed following manufacturer´s 17 
indications. CRITICAL STEP: The inactivation reagent is added to the 18 
mock reactions to account for any bias it may introduce in the qPCR 19 
reaction.  20 
41. Using random hexamers, reverse transcribe 5ul of the eRIC-RNA and 21 
input samples from previous step. Include a no reverse transcriptase 22 
(RT) control to assess the occurrence of gDNA contamination due to 23 





from previous step simultaneously and identically but replacing the 1 
RT enzyme by water.  2 
42. Determine by qPCR the levels of GAPDH mRNA, ACTB mRNA, 18S 3 
rRNA and 28S rRNA in eRIC-RNA and inputs. Simultaneously, asses 4 
the degree of gDNA contamination in eRIC-gDNA samples using the 5 
same GAPDH and ACTB primers. Sequence of primers for human 6 
and mouse are provided in ‘eRIC quality control reagents’ (Table 2 7 
and 3). The qPCR set up is indicated below. The ‘anticipated results’ 8 
section described the expected outcomes of this analysis. 9 
  10 
Component    Amount per reaction 11 
SYBR Green PCR Master Mix  5 μL (final: 1X) 12 
Sample diluted 1:50-1:100  5 μL 13 
100 μM forward primer   0.05 μL (final: 0.5 μM)  14 
100 μM reverse primer   0.05 μL (final: 0.5 μM) 15 
    16 
Use the following thermal cycling parameters: 17 
Step 1 50 °C, 02:00 min 
Step 2 95 °C, 10:00 min 
Step 3 95 °C, 00:15 min 
Step 4 60 °C, 01:00 min 
Perform 40 cycles of steps 3 and 4. 18 
43. If RNA/DNA quality controls are satisfactory, combine the RNase-19 
treated eluates of each round of capture (step 32) to perform the 20 






Assessment of RBP capture: 2d 1 
44. Take the RNase-treated eluates from step 32. Adjust them to the 2 
same RNA concentration determined for heat eluates (step 36) and 3 
final volume using 1x RNase solution (see step 32). Use the sample 4 
with the lowest concentration as reference.  5 
PAUSE STEP: Samples can be frozen at -20 °C indefinitely. 6 
 7 
45. Analyze by SDS-PAGE followed by silver staining (Fig.4b) and 8 
Western blotting with antibodies against known RBPs (e.g. PTBP1) 9 
and negative controls (e.g. ACTB, histone H3). In addition to eluates, 10 
load 0.01-0.05% of inputs (step 12) for comparative purposes. 11 
Recommended sample amounts for these analyses are provided in 12 
Fig.1 and 4. Information of recommended antibodies is provided in 13 
Table 1.    14 
CRITICAL STEP: proceed to the next steps only if protein, RNA and DNA quality 15 
controls are satisfactory.  16 
TROUBLESHOOTING 17 
Proteomic analysis 18 
Sample concentration. Timing: 60 min 19 
46. Add 0.01 volumes of 10% (wt/vol) SDS to the eluates from Step 44 20 
for a final concentration of 0.1% (wt/vol) SDS. 21 
47. Concentrate equal amounts of each sample using a SpeedVac at 22 
37 °C until a volume of ~100 μL is reached. We recommend 23 





RNase treated eluate equivalent to 15-30 μg of RNA (inferred from 1 
the RNA quantification in step 36; Fig. 1).  2 
CRITICAL STEP: For the complementary total proteome analysis, use material 3 
from step 12. Required protein amount depends on mass spectrometry 4 
workflow and equipment, but we usually process up to 2 μg for unfractionated 5 
samples per mass spec run. More material is usually required if fractionation is 6 
applied (20 µg per 10 fractions). 7 
CRITICAL STEP: If the experiment leads to larger quantities of RNA than those 8 
indicated above, material excess can be used to perform additional quality control 9 
experiments or for validation of candidates from the proteomic approach (see 10 
below by Western blotting as in in step 45. 11 
CRITICAL STEP. Avoid concentrating the samples to volumes lower than 12 
50 μL as RBPs can precipitate. If this occurs, supplement the samples with 13 
water to reach 100 μL and incubate at 37 °C until precipitate dissolves.   14 
PAUSE POINT. Samples can be snap frozen in liquid nitrogen and store 15 
at -80 °C.  16 
 17 
SP3 sample purification. Timing: 3 hours 18 
 19 
48. Sample clean up (Steps 48-57). Add 2 μL of 500 mM TCEP (final 20 
concentration 10 mM) to the 100 μL of sample from step 47 to disrupt 21 
disulfide bonds. Mix by pipetting and incubate at RT for 30 min. 22 
49. Add 10.2 μL of 500 mM CAA to alkylate the sulfhydryl groups and 23 
prevent re-formation of the disulfide bridges. Mix by pipetting and 24 





50. Add 10 μL of SP3 purification beads (see “SP3 purification bead stock 1 
preparation”) to each sample. 2 
51. Add 409.1 μL of 100% ACN to obtain a final percentage of 77% 3 
(vol/vol) ACN. Incubate for 30 min at RT.  4 
52. Collect the beads with a magnet and wait until the supernatant is 5 
clear. At this stage, proteins are bound to the SP3 purification beads. 6 
You can either keep the supernatant for quality control purpose or 7 
discard it if the protocol has already been implemented successfully. 8 
53. Keep the tubes on the magnetic rack and add 1 mL of 70% (vol/vol) 9 
EtOH [Wash buffer 1]. Incubate for 30 seconds and discard the 10 
supernatant. Do not resuspend the beads or take the tube off the 11 
magnet.  12 
54.  Keeping the tubes on the magnet, add 1 mL of 70% (vol/vol) EtOH 13 
and incubate for 30 seconds on the magnetic rack. Remove and 14 
discard supernatant. 15 
55.  Keeping the tubes on the magnetic rack, add 1 mL of 100% ACN 16 
[Wash buffer 2] and incubate for 15 seconds on the magnetic rack. 17 
Remove and discard the supernatant. 18 
56. Repeat steps 53-55 seven times. 19 
CRITICAL STEP: It is crucial that at this step, samples are free of any residual 20 
detergent, which will negatively affect the nanoflow HPLC system performance 21 
and consequentially protein identification.    22 
57. Remove any residual ACN. Take the tubes with the beads off the 23 
magnetic rack and proceed immediately to the next step. 24 





58. Resuspend the SP3 purification beads in 50 μL (SILAC) or 10 μL 1 
(TMT) of Trypsin digestion buffer. Avoid excessive pipetting of the 2 
beads as they can stick to the tips, causing protein loss.  3 
CRITICAL STEP: Avoid TEAB when using TMT as primary amines of TEAB can 4 
quench TMT peptide labelling (see Trypsin digestion buffer in ‘Reagent setup’). 5 
59. Add 250 ng of sequencing grade trypsin to each sample and incubate 6 
in a thermal block at 37 °C and 400 rpm, overnight (~14 hours). 7 
60. Collect the beads with a magnet and transfer the supernatant 8 
containing the tryptic peptides to a new tube (this is referred to as SP3 9 
eluate 1). 10 
61. Take the tube off the magnetic rack, re-suspend the beads with 1 mL 11 
100% ACN, and incubate 5 min at RT. Collect beads with magnet and 12 
discard the supernatant. 13 
62. Resuspend the beads in 20 µL of SP3 elution buffer. Incubate for 5 14 
min at RT.  15 
CRITICAL STEP: The composition of the SP3 elution buffer for SILAC or TMT 16 
approach is different (See ‘Reagent setup’). 17 
63. Collect beads with a magnet making sure the solution becomes clear, 18 
carefully collect the supernatant (referred to as SP3 eluate 2), without 19 
disturbing the bead pellet, and combine with SP3 eluate 1 (step 60). 20 
Mix gently by pipetting up and down. If using TMT, proceed to step 21 
64. If using SILAC (or a label-free approach) proceed directly to step 22 
70 if fractionation is required or to 72 if it is not required.  23 





64. Select the kit required for your experimental design based on the 1 
number of conditions and replicates: i.e. Duplex TMT, Sixplex TMT, 2 
TMT10plex, TMT11plex or TMTpro 16plex for up to 2, 6, 10, 11 or 16 3 
samples, respectively. While we have not tested TMTpro 16plex with 4 
this protocol yet, we do not anticipate any incompatibility.  Although 5 
the process is explained in detail in the manufacturer’s manual, we 6 
describe it here in the context of our experimental design.  7 
65. Dissolve 0.8 mg of each TMT label in 42 μL 100% ACN. One unique 8 
label will be used for each sample.  9 
66. Add 4 μL of label solution to each sample and incubate for 1 hour at 10 
RT. 11 
67. Terminate the reaction by adding 5% (wt/vol) hydroxylamine for 15 12 
min at RT. 13 
68. Combine equal amounts of each sample. 14 
69. Clean up the peptides with an OASIS HLB µElution Plate following 15 
manufacturer´s indications.   16 
Sample fractionation. Timing: 2 hours  17 
CRITICAL: If using TMT or samples with high dynamic range between nuclear 18 
and cytoplasmic proteins (e.g. T lymphocytes), we strongly recommend 19 
fractionation. 20 
70. Dry the sample completely by vacuum centrifugation. Reconstitute in 21 
20 μL of 20 mM ammonium formate pH 10.0. 22 
71. Fractionate samples into 5-6 fractions. We typically perform an offline 23 
high pH reverse phase fractionation on an Agilent 1200 Infinity high-24 





C18 column (3 μm, 110 Å, 100 × 1.0 mm2, Phenomenex) or in 1 
StageTips54. 2 
CRITICAL STEP: These parameters are provided for guidance and other 3 
fractionation regimens or approaches can be used. We do not recommend 4 
fractionation at the protein level using SDS-PAGE, as RBPs tend to concentrate 5 
at 220-100 KDa and 75-50 KDa, resulting in poor protein spread across fractions. 6 
We thus recommend fractionation at peptide level using high pH reversed-phase 7 
chromatography 54, isoelectric focusing 56 or ion exchange 55 . 8 
Peptide identification and quantification by LC–MS. 1 day. 9 
72. Dry the sample by vacuum centrifugation. Reconstitute in 20 μL of 10 
loading buffer (5% (vol/vol) DMSO and 5% (vol/vol) formic acid).  11 
73. We recommend performing a pilot run with 10% of sample to estimate 12 
the volume needed for maximum protein identification without 13 
overloading the nanoflow HPLC system. This can be estimated based 14 
on overflow of the sample peptides to the subsequent blank run with 15 
digested BSA (see ‘Experimental Design’).  16 
74. Based on the results from the pilot run, inject the optimal volume into 17 
the LC-MS and separate the digested peptide using a typical gradient 18 
for the available mass spectrometry instrumentation.  19 
Data analysis. Timing: 1 week 20 
CRITICAL Data analysis can be performed on multiple platforms, including 21 
MaxQuant57, R packages or Perseus. Here we describe the workflow based on 22 
the R package LIMMA but the workflow will be similar using other tools. An R 23 





labelled experiment15, is provided as Supplementary Software and 1 
Supplementary Note. 2 
75. Analyze the raw data with software based on database searching that 3 
also performs intensity-based quantitation. We used MaxQuant57 4 
(version 1.6.3.4). Define the search database (in our case Uniprot, 5 
Human, Organism ID 9606, downloaded on 16/01/13). Define the 6 
search parameters: trypsin as protease with full tryptic specificity and 7 
a maximum of two missed cleavage sites, carbamidomethyl (C) as a 8 
fixed modification, and acetylation (protein N-term, i.e. only the amino 9 
terminus of the protein) and oxidation (M) as variable modifications. 10 
All other parameters were used as default. By default, MaxQuant will 11 
filter the results with a 1% FDR at both the PSM (peptide to spectrum 12 
match) and protein level. If working with multiple fractions per sample, 13 
define fraction number in the fraction column before using the ‘match 14 
between runs’ option. For SILAC-based analyses set up the SILAC 15 
labels in the ‘group specific parameters’ tab using the multiplicity 16 
option. For isobaric labelling, navigate to the ‘Group-specific 17 
parameters’ tab and select 'Reporter ion MS2' from the ‘Type’ drop 18 
down menu. Then select appropriate kit (e.g. TMT10plex). Consult 19 
reference57 for more details. 20 
76. Extract the intensities for each peptide from the resulting 21 





77. Add the list of reference protein sequences in FASTA format in 1 
‘Global parameter-sequence’. Use uniquely mapped peptides and 2 
summarize the ion count for each individual sample. 3 
78. Perform multidimensional scaling to determine closeness of samples 4 
in an unbiased way e.g. plotMDS in LIMMA. Biological samples within 5 
the treatment condition should cluster together. Clustering will help to 6 
identify technical problems including batch effects and labelling 7 
biases. 8 
79. Optional: If a batch effect is detected (Fig. 5a-b), we recommend 9 
applying a ‘batch correction’ to the data. This can be incorporated in 10 
the R package LIMMA with an appropriate design matrix before linear 11 
modeling.  12 
CRITICAL STEP: A batch effect can be detected because samples cluster not 13 
because of the treatment, but due to a technical reason, such as differences 14 
between replicates, independent mass spectrometry runs, or labelling 15 
performance (Fig. 5a-b). As with any data manipulation, batch effect removal can 16 
distort data, hence should be applied only if a clear batch effect is detected by 17 
principal component analysis. In our experience, the SILAC light label can 18 
introduce batch effects in some instances as exogenous contaminants (e.g. 19 
keratins) and unlabeled peptides will only be present in the light channel. This 20 
potential bias is minimized by the permutation of the SILAC labels but, if 21 
problematic, it can easily be removed by applying the batch effect correction to 22 
the SILAC labels. 23 





81. Using at least 3 biological replicates, use LIMMA to test whether the 1 
fold changes between conditions are different from ‘zero’ using a 2 
moderated t-test. 3 
82. Correct the p-values for multiple testing by the Benjamini-Hochberg 4 
procedure. Use 1% and 10% FDR proteins to define ‘high-confidence’ 5 
and ‘candidate’ responsive RBPs. We have recently shown that a 6 
large proportion of the 10% FDR responsive RBPs are truly regulated 7 
by the cue (in this case, by virus infection)15. Nevertheless, we 8 
recommend orthogonal validation experiments when working with 9 
‘candidate’ responsive RBPs.  10 
83. Optional: Proteins that are not detected in all conditions or replicates 11 
can lead to ‘zero’ or ‘infinite’ ratios, eliminating these proteins 12 
effectively from the statistical analysis. As these proteins can 13 
represent biologically important on/off and off/on states, we used a 14 
semi-quantitative analysis that considers the replicability of these 15 
‘zero’ and presence of intensity signal in control and treatment 10,15, 16 
as implemented in the R markdown provided in the  Supplementary 17 
Software and Supplementary Note. Alternatively, imputation 18 
methods59 that add a value to each ‘zero’ can be used. The 19 
advantages and disadvantages of each option are described in the 20 
‘experimental design’.  21 
CRITICAL STEP: The comparison between UV-irradiated and non-irradiated 22 
samples is used to discover the repertoire of RBPs present in a given biological 23 





against non-irradiated samples as signal in these samples is low and noisy and 1 
creates artificial distortions of the data when used as normalizer. 2 
84. Optional: If complementary proteomic analysis of the input was 3 
performed, process the sample as described in Step 47-83 for 4 
eluates. Then subtract the log2 fold intensity of the input from the log2 5 
fold intensity of the eluate to estimate eluate/input ratios.  6 
 7 
TROUBLESHOOTING  8 
Troubleshooting advice can be found in Table 4. 9 
Table 4. Troubleshooting table. 10 




SILAC incorporation not 
sufficient 
 
Incubate cells longer in SILAC media. 
If the cells do not tolerate SILAC 
reagents, switch to TMT or other 
quantitative method. 
 









Too high protein 
concentration in lysates 
Apply more pressure when passing 
lysate through needle. 
Repeat homogenization cycles or 
explore other homogenization 





Increase lysis volume until lysate 













shearing of chromatin 
 
 
Presence of insoluble 














Increase length and/or temperature 
of pre-elution step, controlling in 
parallel for poly(A) RNA lost.  
38, 42 RNA 
degradation 
Residual RNase activity in 














Excessive UV irradiation 
Add RNasin (Promega, N2511) or 
RNase inhibitors e.g. ribonucleoside 
vanadyl complex (NEB, S1402S) to 
the lysis buffer. Note that 
ribonucleoside vanadyl complexes 
are incompatible with EDTA. Hence, 
when working with this RNase 
inhibitor prepare a lysis buffer without 
EDTA. Following wash buffers can 
contain EDTA. 
Decrease temperature to 4 °C during 
capture and the first two washes. 
Remaining washes can be performed 
at 37 °C due to RNase dilution during 
previous washes. 
If eRIC captures substantially more 





irradiated samples, further optimize 
the UV dosage. Make sure the UV 
sensor is not occluded, which would 
lead to UV overdose.  
38, 
42, 45 
Low RNA and 
protein yield in 
eluates 




















Increase the length of the capture 
step, reduce hybridization and/or pre-
elution temperature. Increase the 
number of LNA2.T capture cycles 
(typically from 2 to 3) and/or the 
amount of beads to ensure full 
depletion of poly(A) RNA.  
 
See “RNA degradation” in 
troubleshooting. 
45, 74 Low protein 
recovery 
Insufficient cross-linking Replace UV bulbs, optimize UV 
irradiation dose, in particular, for 
thicker samples or samples 
containing UV-absorbing pigments. 
82-83 High level of 
infinite and zero 
protein ratios in 
Proteins with low 
abundance are not 
identified in all samples 
Use more material if MS has not 
reached saturation. Perform mass 







mass spectrometer or use more 
fractions to gain better coverage.  
 
If the ‘zeros’ follow a pattern that 
resembles a biological regulation (i.e. 
on/off or off/on states), use a 
semiquantitative approach or apply 
suitable data imputation to the 
dataset. 






Batch effect, sample 
collection or mass 
spectrometry run 
Perform multidimensional scaling 
analysis to identify the dominant 
factor of the batch effect. Employ 
batch correction algorithms to 
eliminate batch effects, for example 
by implementing an appropriate 
design matrix in the LIMMA package 
before linear modelling. If an 
experiment is technically inferior due 
to substantially lower identification 
and quantification rate (batch effect 
due to the mass spec run), we 
recommend first use batch correction 
and if this does not help, substitute 
the replicate. 
 1 
TIMING  2 
Coupling of the LNA2.T probe to beads, 8 h 3 





(Optional) SILAC labelling Step 1-3, 14 days 1 
Cell preparation for RIC: Step 4, 1-2 days 2 
UV irradiation and cell lysis: Step 5-6, 1-2 h 3 
Lysate homogenization: Step 7-9, 1 h 4 
RNP capture: Step 10-26, 2-4 h 5 
RNase based elution: Step 28-32, 60-90 min 6 
Heat based elution: Step 27, 33-34, 15 min 7 
Quality control analyses 8 
RNA and DNA analysis: 35-43, 2 days 9 
Assessment of RBP capture: Step 44-45, 2 days 10 
Proteomic analysis 11 
Sample concentration: Step 46-47, 60 min 12 
Sample preparation by SP3: Step 48-57, 3 h 13 
Trypsin digestion and peptide elution: Step 58-63, 15-17 h 14 
(Optional) TMT labelling Step 64-69, 2 h 15 
(Optional) Sample fractionation: Step 70-71, 2 h 16 
Peptide identification and quantification by LC-MS: Step 72-74, 1 day 17 
Data analysis: Step 75-84, 1 week 18 
 19 
ANTICIPATED RESULTS 20 
 21 
Initially, RIC was used to identify the RBPs that bind to poly(A) RNA in cells and 22 
organisms1,2,4,6,7,9-12,14,15,35,36. RBDmap was derived from RIC and applied to 23 
discover the protein regions that directly interact with RNA31,32. The recently 24 
developed eRIC protocol boosts RIC selectivity for poly(A) RNA by including 25 
locked nucleotides in the oligo(dT) probe14. We exploit here this improved RIC 26 





analysis10,14,15 to enable system-wide profiling of RBP dynamics in response to 1 
biological cues. 2 
A critical aspect of RIC and eRIC is that the eluates should be strongly enriched 3 
in intact polyadenylated RNA. To assess whether poly(A) is predominant in 4 
eluates and is not degraded, we first use a Bioanalyzer with an RNA 6000 Pico 5 
Kit (Fig. 4a). In a successful eRIC experiment, the bioanalyzer profile should 6 
show a strong reduction in the rRNA peaks, especially for the 28S rRNA (~4,000 7 
nt), when compared to the inputs (Fig. 4a). Moreover, the eluate RNA profile 8 
should show a ‘bulge’ composed of RNAs with heterogeneous sizes (as expected 9 
for mRNAs) that peaks between 500-4,000 nt (Fig. 4a). RNA degradation is 10 
highlighted by a strong reduction of the 500-4,000 nt mRNA ‘bulge’ to smaller 11 
RNA fragments (50-500 nt) in eluates. 12 
If eRIC enriches for intact poly(A) RNA based on the bioanalyzer profile, we then 13 
utilize RT-qPCR and qPCR for detailed characterization of the isolated RNA pool. 14 
We measure the levels of mRNAs (GAPDH and ACTB) and rRNAs (28S and 15 
18S) in inputs and eluates to quantitatively assess the degree of poly(A) RNA 16 
enrichment over non-polyadenylated RNA. We expect a 100- and 10-fold 17 
enrichment of mRNAs (e.g. GAPDH and ACTB) over 28S and 18S rRNA, 18 
respectively2,14. Moreover, if gDNA is depleted in eluates the Ct value in -RT 19 
samples should be null or at least 10 Ct higher than those observed in +RT 20 
samples2,14. To obtain a system-wide snapshot of the RNA content, inputs and 21 
eluates can further be analyzed by RNAseq. This analysis will reveal the relative 22 
abundance of each RNA biotype as well as each individual RNA species, 23 





Once the quality of the isolated RNA has been controlled, it is critical to assess if 1 
RBPs have been co-purified efficiently. To test this, we first use silver staining 2 
due to its relatively high sensitivity. The eluates of a successful eRIC experiment 3 
should yield a complex protein pattern, while the lane corresponding to the non-4 
irradiated control should remain clean (Fig. 4b). Moreover, the protein pattern in 5 
eluates should strongly differ from that in inputs, showing the enrichment of a 6 
specific subset of proteins. For comparative eRIC analyses, it is important to 7 
perform pilot experiments to test if the eluates display similar protein patterns and 8 
if individual differences can be spotted. Note that silver staining will only detect 9 
the most abundant proteins in eluates, which often play housekeeping roles. 10 
Hence, it is not expected to detect massive differences between conditions using 11 
silver staining (Fig. 4b)10,15. Therefore, the silver staining analysis is a time-12 
efficient approach to assess the overall performance of eRIC in different 13 
experimental settings and can be used to instruct the design of a comparative 14 
eRIC experiment. 15 
To further assess the selectivity of eRIC, we also employ Western blotting with 16 
antibodies against well-established RBPs (e.g. PTBP1 and/or HNRNPC) and 17 
negative controls (e.g. ACTB and histone H4). While both types of proteins should 18 
be detected in inputs, only bona fide RBPs should be present in eluates and their 19 
presence should be UV-dependent. Detection of non-RBPs such as ACTB in 20 
eRIC eluates is a clear indication that further optimization is required (see 21 
Troubleshooting).  22 
Only if RNA and protein analyses support the successful 23 
implementation/adaptation of eRIC, it is recommended to proceed with the 24 





1,000 proteins with the workflow and equipment described here. Only proteins 1 
within the UV-irradiated samples which are reproducibly enriched over the non-2 
irradiated control should be considered as high-confidence RBPs. As a reference, 3 
we only classify proteins as RBPs if they are enriched in the eluates of 4 
UV-irradiated samples with 1% FDR. Several RBPomes have been established 5 
in different cell lines and species (collected in 25). This super-dataset can be used 6 
as reference to quality control the proteomic results. In other words, an RBPome 7 
of excellent quality is expected to overlap heavily with previously established 8 
RBPomes from the same or closely related cell types. Moreover, both newly and 9 
previously established RBPomes are expected to be enriched in similar gene 10 
ontology (GO) terms and protein domains, which will indeed be dominated by 11 
RNA-related annotation and RNA-binding domains. For example, RNA 12 
recognition motif (RRM), K-homology domain (KH), and other RNA-binding 13 
domains, should rank amongst the most prevalent domains present in the 14 
RBPome1,2,31. By contrast, DNA-binding proteins should be underrepresented, 15 
even though specific DNA binders may be endowed with dual DNA/RNA-binding 16 
activity and will thus crosslink to RNA (e.g. HNRNPU, EDF1, SUB1). These 17 
enrichment analyses can be performed with freely available tools such as  18 
DAVID64 (https://david.ncifcrf.gov) and AmiGO 2 19 
(http://amigo.geneontology.org/amigo) as well as dedicated R packages e.g. 20 
topGO (https://doi.org/doi:10.18129/B9.bioc.topGO).  21 
Comparative eRIC analysis will discover RBPs that associate with RNA 22 
differentially under distinct experimental conditions. The number of RBPs 23 
regulated by a given cue can vary depending on the strength of the stimulus and 24 





typically classify these proteins as ‘high confidence’ or ‘candidate’ dynamic RBPs 1 
if passing the 1% or 10% FDR cut-off, respectively (Fig. 5c-d). To confirm that 2 
these proteins have differential RNA-binding properties under the selected 3 
experimental conditions, we repeat the RIC experiment and analyze few selected 4 
dynamic RBPs by Western blotting. Note that, for this validation approach the 5 
samples should be processed separately, as described in the TMT workflow. 6 
Applying this approach to SINV-infected cells, we validated the differential RNA-7 
binding activity of 11 RBPs (both 1% and 10% FDR) out of 11 proteins tested, 8 
supporting the excellent correlation between proteomics and Western blot data15. 9 
Nevertheless, the abundance of some RBPs in eRIC eluates can be low, making 10 
their detection by Western blotting difficult. For these cases we recommend 11 
increasing the amount of sample loaded in the gel and employing ultra-sensitive 12 
enhanced chemiluminescent (ECL) reagents (e.g. SuperSignal West Femto 13 
Maximum Sensitivity Substrate, Thermo Fisher Scientific). In addition to these 14 
experiments, we recommend further validation with orthogonal methods such as 15 
polynucleotide kinase assay1,4,5, fluorescence-based assays2,31,65, RIP or CLIP 16 
combined with RT-qPCR, CLIPseq-based approaches or localization studies15.  17 
To assess the overall impact of protein abundance on eRIC results, we 18 
recommend analyzing the whole cell proteome by mass spectrometry (i.e. inputs) 19 
(Fig. 3 and 5e-f). By relating the levels of proteins in the inputs and eluates, it is 20 
possible to elucidate if the differential association of a given RBP with RNA 21 
correlates with matching changes in protein abundance (Fig. 5c vs e). In other 22 
words, if there is more protein, more protein is expected to be bound to RNA, and 23 
vice versa10,15. For example, protein abundance drives most of the alterations 24 





has minor impact in SINV-infected cells15 (Fig. 5c vs e). Importantly, even under 1 
conditions where protein abundance drives the remodeling of the RBPome, it is 2 
possible to identify individual RBPs that are apparently regulated in an 3 
abundance-independent manner10. This analysis is the first step towards 4 
understanding how a given RBP responds to a biological cue. 5 
Alterations in the activity of an RBP can also be triggered by changes in the 6 
availability of its RNA targets. Hence, we also recommend performing parallel 7 
RNAseq analysis of the inputs and/or eluates of the eRIC experiment. This 8 
analysis will reveal if the biological cue causes pervasive, subtle or no changes 9 
in RNA abundance. For example, we recently discovered that SINV infection 10 
causes a massive degradation of cellular mRNAs15. This phenomenon occurs in 11 
parallel with the emergence of the viral RNA, which becomes the dominant mRNA 12 
in the cell. Taken together, cellular RNA degradation and accumulation of viral 13 
RNA causes deep remodeling of the cellular RBPome. While virus infection has 14 
a global impact on RNA availability, other biological cues may cause more subtle 15 
differences. In such circumstances, it is possible to utilize RIP or CLIP (e.g. 16 
iCLIP66, PAR-CLIP67, eCLIP68 and other variants) data to elucidate if the changes 17 
in activity of a given RBP can be explained by matching changes in its target 18 
RNAs. For this, it is already possible for many RBPs to use available data such 19 
as the eCLIP repository in ENCODE 20 
(https://www.encodeproject.org/search/?type=Experiment&status=released&int21 
ernal_tags=ENCORE&assay_title=eCLIP)69   22 
Other mechanisms may also contribute to RBP control. RBDs are strongly 23 
enriched in post-translational modifications (PTMs)31,70, suggesting that PTMs 24 





studies with proteome-wide methods to profile PTMs can be very powerful to 1 
elucidate the contribution of PTMs to RBP function. Similarly, RBPs can 2 
assemble into different complexes in response to biological cues. For example, 3 
the glutamyl-prolyl tRNA synthase (EPRS) is released from the tRNA 4 
multisynthetase complex upon interferon γ-induced phosphorylation, and 5 
assembles with GAPDH, SYNCRIP and rpL13a forming the GAIT complex71. This 6 
newly formed complex regulates translation of specific pro-inflammatory mRNAs. 7 
It is thus plausible that differential protein complex assembly has a broader 8 
regulatory role of RBP activity than previously anticipated. Hence, protein-protein 9 
interaction analyses under the conditions of the eRIC experiment can shed light 10 
on the relevance of this regulatory mechanism in RBP function.  11 
In summary, the comparative eRIC approach described here can be applied to 12 
virtually any eukaryotic system or experimental condition to discover RBPs with 13 
condition-specific regulatory roles. By expanding comparative eRIC studies, it will 14 
be possible to understand in greater detail how cells and, ultimately organisms, 15 
adapt to an ever-changing environment. 16 
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Raw and processed proteomic data is deposited to the ProteomeXchange 1 
Consortium via the PRIDE partner repository with the dataset identifier 2 
PXD009789. Original data was generated in15 and was re-analyzed here to 3 
illustrate the analytical workflow presented in Figure 3 and 5. 4 
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FIGURE LEGENDS 23 
Figure 1. Schematic representation of eRIC. Cultured cells are exposed to UV 24 





lines) bound at ‘zero distance’. Cells are then lysed under denaturing conditions 1 
and poly(A) RNAs with their associated proteins are captured using oligo(dT) 2 
probes modified with LNAs and coupled to magnetic beads. Extensive washes 3 
and a pre-elution in pure water are applied to eliminate contaminant proteins 4 
(black lines), as well as contaminating RNA and gDNA. After the pre-elution, the 5 
bead suspension containing the captured material is split into two aliquots, which 6 
are subjected to either heat or RNase-mediated elution. Heat- and RNase-eluted 7 
samples are used for RNA/DNA and protein analyses, respectively.  8 
     9 
Figure 2. Overview of the proteomic workflow. Schematic representation of 10 
SILAC- (left) and TMT-based (right) comparative eRIC experiments. In the SILAC 11 
approach, proteins are labelled ‘in cellulo’ by incubation of cells with media 12 
containing isotopically distinct amino acids. Samples are mixed immediately after 13 
cell lysis, so eRIC and downstream sample preparation for proteomics is 14 
performed with the combined samples. In the TMT approach, peptide labelling is 15 
performed after eRIC elution. Hence, RBP isolation and sample preparation for 16 
proteomics are performed individually for each experimental condition.    17 
 18 
Figure 3. Assessment of relative RNA binding by total proteomics and RIC. 19 
a) Scatter plot comparing the protein intensities in the eluates of two replicates of 20 
a comparative RIC experiment. Two RBPs with similar abundance are highlighted 21 
(E2 in blue and nsP2 in red). b) as (a) but displaying the protein intensity of 22 
proteins detected in inputs (total cellular proteome). The two highlighted proteins 23 





intensity ratio between RIC eluates and inputs. The comparison highlights that 1 
nsP2 displays stronger relative RNA binding than E2. WCL, whole cell lysate.  2 
 3 
Figure 4. eRIC quality controls. Poly(A) RNA and associated RBPs were 4 
purified from proliferating human leukemia cells (Jurkat) with eRIC and analyzed 5 
as follows. a) Representative bioanalyzer profiles of RNA extracted from input 6 
material (top), eRIC pre-eluates (middle), and eRIC heat-eluted samples 7 
(bottom). rRNAs, tRNAs and small RNAs are predominant in inputs and still 8 
present in pre-eluates. eRIC heat-eluted samples display a strong enrichment of 9 
RNA species with a size range characteristic of mRNAs. Both 28S rRNA and the 10 
small RNAs are undetectable in the heat eluates, although a residual amount of 11 
18S rRNA is consistently observed. [FU] fluorescent units, [nt] length of RNA in 12 
number of nucleotides. b) eRIC was performed on Jurkat cells incubated for 6 h 13 
with 0.5 mM of the -ketoglutarate antagonist dimethyloxalylglycine (DMOG) or 14 
vehicle (DMSO). Aliquots of the RNase-eluted samples and inputs were analyzed 15 
by SDS-PAGE and silver staining. Except for the RNase A and T1 bands (~15 16 
KDa), proteins are only detected in eRIC eluates if cells were UV-irradiated. 17 
Protein patterns in untreated and DMOG-treated samples are virtually 18 
indistinguishable, which agrees with the proteomic results that revealed a very 19 
limited RBP pool (61 proteins out of 721) responding to DMOG14.  20 
 21 
Figure 5. Statistical analysis of proteomic data. a) Unbiased clustering of data 22 
using multidimensional scaling of 3 biological replicates (1-3) and 2 different 23 
conditions (Mock in black and Treatment [SINV virus infection] in red). In this 24 





than experimental conditions, suggesting that the dataset has a batch effect. 1 
Batch effects can potentially hide the underlying biological signal and we 2 
recommend investigating their cause e.g. assessing if the mean intensity 3 
between mass spectrometry runs differ. If the cause of the effect can be identified, 4 
a batch correction algorithm can be used after data acquisition. b) 5 
Multidimensional scaling as above. In this example, RIC eluates from control 6 
(mock) samples cluster together with a clear separation from the treated 7 
(infected) samples. No batch correction is necessary in this case. However, the 8 
RIC eluate from treated cells in the replicate 3 displays a differential signature 9 
when compared to the other 2 replicates. Detailed analysis of the proteomic data 10 
can help to elucidate whether this results from a technical problem (e.g. an error 11 
estimating the amount of protein prior to mixing the samples). c) Scatter plot 12 
displaying the treated/untreated protein ratios from two independent replicates. A 13 
good correlation between replicates indicates the high quality of the experiment. 14 
Every dot represents a protein and they are colored based on the statistical 15 
significance of the change between the two conditions (1%, 5% and 10% FDR). 16 
d) Volcano plot displaying the fold change and p value of the proteins in (c). Every 17 
dot corresponds to a protein and they are colored based on the statistical 18 
significance of the change between the two conditions (1%, 5% and 10% FDR. 19 
e) as (c) but displaying the ratios in the whole cell lysate (input). No significant 20 
changes were observed during the time-course of the treatment, suggesting that 21 
the changes observed in eluates are not due to matching changes in protein 22 
abundance. Original data was generated in 15 and was re-analyzed here to 23 





is displayed in panel a, c and d. Panel b and e represents the matching input 1 
proteome. 2 
   3 
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